WO2020061303A1 - Pyrazolylacylpyrazoline compounds and method for treating pain - Google Patents
Pyrazolylacylpyrazoline compounds and method for treating pain Download PDFInfo
- Publication number
- WO2020061303A1 WO2020061303A1 PCT/US2019/051920 US2019051920W WO2020061303A1 WO 2020061303 A1 WO2020061303 A1 WO 2020061303A1 US 2019051920 W US2019051920 W US 2019051920W WO 2020061303 A1 WO2020061303 A1 WO 2020061303A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- compound
- alkyl
- substituted
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 185
- 238000000034 method Methods 0.000 title claims description 127
- 208000002193 Pain Diseases 0.000 title claims description 17
- 230000036407 pain Effects 0.000 title claims description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 68
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 178
- 125000001072 heteroaryl group Chemical group 0.000 claims description 54
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 50
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 39
- -1 methoxy-phenyl Chemical group 0.000 claims description 38
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- LTPORTOBCHZKOJ-UHFFFAOYSA-N 3-pyrazol-4-ylidenepyrazole Chemical compound N1=NC(C=C1)=C1C=NN=C1 LTPORTOBCHZKOJ-UHFFFAOYSA-N 0.000 claims description 23
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 22
- 239000005711 Benzoic acid Substances 0.000 claims description 20
- 235000010233 benzoic acid Nutrition 0.000 claims description 20
- 125000004076 pyridyl group Chemical group 0.000 claims description 20
- 210000002569 neuron Anatomy 0.000 claims description 17
- 125000001475 halogen functional group Chemical group 0.000 claims description 16
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 16
- 239000011148 porous material Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 230000004850 protein–protein interaction Effects 0.000 claims description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 102000004310 Ion Channels Human genes 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 7
- 125000003944 tolyl group Chemical group 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 abstract description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 66
- 238000005481 NMR spectroscopy Methods 0.000 description 50
- 239000000203 mixture Substances 0.000 description 50
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 46
- 239000007787 solid Substances 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 229910001868 water Inorganic materials 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 16
- 101000935123 Homo sapiens Voltage-dependent N-type calcium channel subunit alpha-1B Proteins 0.000 description 16
- 229940126543 compound 14 Drugs 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 239000000651 prodrug Substances 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 102100025342 Voltage-dependent N-type calcium channel subunit alpha-1B Human genes 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
- 229940125782 compound 2 Drugs 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 101150104494 CAV1 gene Proteins 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 108090000862 Ion Channels Proteins 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000009610 hypersensitivity Effects 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 238000001768 microscale thermophoresis Methods 0.000 description 4
- 229960005181 morphine Drugs 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 4
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 3
- CPZGPYRTJRDUPX-UHFFFAOYSA-N 4-(1,2-dihydropyrazol-3-ylidene)pyrazole Chemical compound C1=CNNC1=C1C=NN=C1 CPZGPYRTJRDUPX-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- UMRUCNWUKYTMTO-UHFFFAOYSA-N [5-(4-methoxyphenyl)-3-[3-(4-methylphenyl)-1-phenylpyrazol-4-yl]-3,4-dihydropyrazol-2-yl]-[3-(2H-tetrazol-5-yl)phenyl]methanone Chemical compound COc1ccc(cc1)C1=NN(C(C1)c1cn(nc1-c1ccc(C)cc1)-c1ccccc1)C(=O)c1cccc(c1)-c1nn[nH]n1 UMRUCNWUKYTMTO-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- JQJUGTNSRMHPKA-UHFFFAOYSA-N 3-[1-benzyl-3-(4-methylphenyl)pyrazol-4-yl]-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C(C1=CC=CC=C1)N1N=C(C(=C1)C=CC(=O)C1=CC=C(C=C1)OC)C1=CC=C(C=C1)C JQJUGTNSRMHPKA-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 108010063086 avidin-agarose Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002999 depolarising effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229940098895 maleic acid Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- XCFRUDDNXSEECH-UHFFFAOYSA-N methyl 4-[5-(4-methoxyphenyl)-3-[5-(4-methylphenyl)-2-phenylpyrazol-3-yl]-3,4-dihydropyrazol-2-yl]benzoate Chemical compound COC1=CC=C(C=C1)C=1CC(N(N=1)C1=CC=C(C(=O)OC)C=C1)C=1N(N=C(C=1)C1=CC=C(C=C1)C)C1=CC=CC=C1 XCFRUDDNXSEECH-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229940116315 oxalic acid Drugs 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 238000012402 patch clamp technique Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 2
- 229940067157 phenylhydrazine Drugs 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000002972 tibial nerve Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- UVGHPGOONBRLCX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]hexanoate Chemical compound S1CC2NC(=O)NC2C1CCCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- OBQRODBYVNIZJU-UHFFFAOYSA-N (4-acetylphenyl)boronic acid Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1 OBQRODBYVNIZJU-UHFFFAOYSA-N 0.000 description 1
- FQHCPFMTXFJZJS-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine;hydrochloride Chemical compound Cl.COC1=CC=C(NN)C=C1 FQHCPFMTXFJZJS-UHFFFAOYSA-N 0.000 description 1
- DAHIHATYFWNUSP-SDNWHVSQSA-N (E)-1-(4-methoxyphenyl)-3-[3-(4-methylphenyl)-1-pyridin-3-ylpyrazol-4-yl]prop-2-en-1-one Chemical compound COC1=CC=C(C=C1)C(\C=C\C=1C(=NN(C=1)C=1C=NC=CC=1)C1=CC=C(C=C1)C)=O DAHIHATYFWNUSP-SDNWHVSQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RMXSRFLAHUJHEC-SFQUDFHCSA-N (e)-1-(4-methoxyphenyl)-3-[3-(4-methoxyphenyl)-1-phenylpyrazol-4-yl]prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CN(C=2C=CC=CC=2)N=C1C1=CC=C(OC)C=C1 RMXSRFLAHUJHEC-SFQUDFHCSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- FNQBHAYXQLQJLJ-LFIBNONCSA-N (e)-3-[3-(4-bromophenyl)-1-phenylpyrazol-4-yl]-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CN(C=2C=CC=CC=2)N=C1C1=CC=C(Br)C=C1 FNQBHAYXQLQJLJ-LFIBNONCSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- YPJNFWXCCZHQTF-UHFFFAOYSA-N 1-(4-methoxyphenyl)-3-[3-(4-methylphenyl)-1-propan-2-ylpyrazol-4-yl]prop-2-en-1-one Chemical compound C(C)(C)N1N=C(C(=C1)C=CC(=O)C1=CC=C(C=C1)OC)C1=CC=C(C=C1)C YPJNFWXCCZHQTF-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YPXNXBBOBLTDCL-UHFFFAOYSA-N 3-(4-bromophenyl)-1-phenylpyrazole-4-carbaldehyde Chemical compound C1=CC(Br)=CC=C1C1=NN(C=2C=CC=CC=2)C=C1C=O YPXNXBBOBLTDCL-UHFFFAOYSA-N 0.000 description 1
- FTUHJYUSTWIPBN-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-phenylpyrazole-4-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1C1=NN(C=2C=CC=CC=2)C=C1C=O FTUHJYUSTWIPBN-UHFFFAOYSA-N 0.000 description 1
- KGEVSOCXYXEMSM-UHFFFAOYSA-N 3-(4-methoxyphenyl)-1-phenylpyrazole-4-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C1=NN(C=2C=CC=CC=2)C=C1C=O KGEVSOCXYXEMSM-UHFFFAOYSA-N 0.000 description 1
- FYSDRTSQVDPCRN-UHFFFAOYSA-N 3-[3-(4-chlorophenyl)-1-phenylpyrazol-4-yl]-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)C=CC1=CN(C=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1 FYSDRTSQVDPCRN-UHFFFAOYSA-N 0.000 description 1
- KMPDUDIUGIIKNP-UHFFFAOYSA-N 3-[3-(4-methylphenyl)-1-phenylpyrazol-4-yl]-1-(4-pyridin-2-ylphenyl)prop-2-en-1-one Chemical compound C1(=CC=CC=C1)N1N=C(C(=C1)C=CC(=O)C1=CC=C(C=C1)C1=NC=CC=C1)C1=CC=C(C=C1)C KMPDUDIUGIIKNP-UHFFFAOYSA-N 0.000 description 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical group C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
- ARLWCCATGXVLFU-UHFFFAOYSA-N 4-[5-(4-methoxyphenyl)-3-[5-(4-methylphenyl)-2-phenylpyrazol-3-yl]-3,4-dihydropyrazol-2-yl]benzoic acid Chemical compound COC1=CC=C(C=C1)C=1CC(N(N=1)C1=CC=C(C(=O)O)C=C1)C=1N(N=C(C=1)C1=CC=C(C=C1)C)C1=CC=CC=C1 ARLWCCATGXVLFU-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- DAPNDMDVFBTRPW-UHFFFAOYSA-N 5-[3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-3-(4-methylphenyl)-1-phenylpyrazole Chemical compound COC1=CC=C(C=C1)C=1CC(NN=1)C=1N(N=C(C=1)C1=CC=C(C=C1)C)C1=CC=CC=C1 DAPNDMDVFBTRPW-UHFFFAOYSA-N 0.000 description 1
- 125000003726 6-dimethylamino-2-naphthoyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C1=C([H])C([H])=C2C([H])=C(C(=O)[*])C([H])=C([H])C2=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- GJQLIMKDDKPSIZ-FOWTUZBSSA-N C1(=CC=C(C=C1)\C(\C)=N\NC=1C=NC=CC=1)C Chemical compound C1(=CC=C(C=C1)\C(\C)=N\NC=1C=NC=CC=1)C GJQLIMKDDKPSIZ-FOWTUZBSSA-N 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 0 CC(C1)=NN(*)C1c1c[n](*)nc1* Chemical compound CC(C1)=NN(*)C1c1c[n](*)nc1* 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KCAJOKMGJJTAKA-UHFFFAOYSA-N Cc(cc1)ccc1-c(c(C(C1)N(C(CCC(O)=O)=O)N=C1c(cc1)ccc1OC)c1)n[n]1-c1ccccc1 Chemical compound Cc(cc1)ccc1-c(c(C(C1)N(C(CCC(O)=O)=O)N=C1c(cc1)ccc1OC)c1)n[n]1-c1ccccc1 KCAJOKMGJJTAKA-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical class COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical class CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 101100494815 Rattus norvegicus Cav1 gene Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- MSJHOJKVMMEMNX-UHFFFAOYSA-N benzylhydrazine;hydron;dichloride Chemical compound Cl.Cl.NNCC1=CC=CC=C1 MSJHOJKVMMEMNX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 101150061458 cav gene Proteins 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- CZNGTXVOZOWWKM-UHFFFAOYSA-N methyl 4-bromobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1 CZNGTXVOZOWWKM-UHFFFAOYSA-N 0.000 description 1
- SRXOJMOGPYFZKC-UHFFFAOYSA-N methyl 4-chloro-4-oxobutanoate Chemical compound COC(=O)CCC(Cl)=O SRXOJMOGPYFZKC-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical class O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- CPSCIFXVLXCFIQ-UHFFFAOYSA-N n-(1-phenylethylideneamino)aniline Chemical compound C=1C=CC=CC=1C(C)=NNC1=CC=CC=C1 CPSCIFXVLXCFIQ-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- KKKPCJMDBZKMEY-LFIBNONCSA-N n-[(e)-1-(4-bromophenyl)ethylideneamino]aniline Chemical compound C=1C=C(Br)C=CC=1C(/C)=N/NC1=CC=CC=C1 KKKPCJMDBZKMEY-LFIBNONCSA-N 0.000 description 1
- GBWYSVKAUZHKNN-FOWTUZBSSA-N n-[(e)-1-(4-methoxyphenyl)ethylideneamino]aniline Chemical compound C1=CC(OC)=CC=C1C(\C)=N\NC1=CC=CC=C1 GBWYSVKAUZHKNN-FOWTUZBSSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000008008 oral excipient Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007832 reinnervation Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 239000001962 taste-modifying agent Substances 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- GDJZZWYLFXAGFH-UHFFFAOYSA-M xylenesulfonate group Chemical group C1(C(C=CC=C1)C)(C)S(=O)(=O)[O-] GDJZZWYLFXAGFH-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Definitions
- voltage-gated calcium channels play important and diverse roles in the synaptic transmission of electrical signals (e.g., neurotransmitter release), in the integration and modulation of these signals, and in the transduction of membrane depolarization into intracellular signals.
- neurons express a variety of calcium channels that are composed of large heteromeric assemblies of pore forming al (CaVal) subunits and auxiliary subunits.
- CaV increase the surface expression of voltage-gated calcium channels and regulate their biophysical properties.
- the interaction between pore and auxiliary subunits is driven by protein-protein interactions.
- One such interaction between pore and auxiliary subunits of a voltage-gated ion channel is a tight CaVaDCaV protein-protein interaction.
- Pain is a prevalent problem. Pain can arise from or accompany a wide variety of diseases and disease states. Clinically-approved blockers of voltage-gated calcium channels for pain management are encumbered by numerous off-target effects and exhibit narrow therapeutic windows. A need remains for compounds to treat pain that are both non- addictive and avoid the other drawbacks of existing pain medicines.
- the disclosure relates to a compound of the Formula (1)
- R 1 is selected from the group consisting of -(C1-C4 alkyl)-C0 2 H, -CO2H and tetrazole substituted phenyl
- R 2 is selected from the group consisting of phenyl, methoxy substituted phenyl and pyridinyl
- R 3 is selected from the group consisting of (C1-C3 alkyl) substituted phenyl halo substituted phenyl
- R 4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridine; or a pharmaceutically acceptable salt thereof.
- the disclosure relates to a compound of the Formula (la)
- R la is C(0)R 1 or phenyl optionally substituted with one or more -CO2H, -C(0)OCi-C 4 alkyl, or heteroaryl, wherein R 1 is -C1-C4 alkyl-C02H, -C1-C4 alkyl-C(0)Ci-C4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C 4 alkyl, or heteroaryl;
- R 2 is phenyl, heteroaryl, -C 1 -C 4 alkyl-phenyl, or -C 1 -C 4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C 1 -C 4 alkoxy;
- R 3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C 1 -C 3 alkyl, halo, -C 1 -C 4 alkoxy, or heteroaryl;
- R 4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with C1-C4 alkoxy, piperazinyl, or heteroaryl;
- the disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Formula (1) or Formula (la) , or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier, diluent or excipient.
- the disclosure relates a method to treat a neurological disorder in a mammal in need thereof, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof of a compound of Formula (1) or Formula (la).
- the disclosure relates to a method to modulate a protein-protein interaction between pore and auxiliary subunits of a voltage-gated ion channel in a nerve cell, comprising contacting the nerve cell with an effective amount of the compound of Formula (1) or Formula (la).
- Fig. 1 shows a fluorescence polarization assay used to determine an inhibition constant for compounds 6 and 14.
- Fig. 2 shows a binding curve that emerged from the use of microscale thermophoresis to establish direct binding of compound 6. Curve fitting analysis led to a dissociation constant of 3.6 ⁇ 1.1 mM.
- Fig. 3 shows compound 6 does not inhibit the protein-protein interaction between Cav 3 Arg-307-Ala as evidenced by a lack of displacement of fluorescently-labeled Cavai- AiD bound to the mutated Cav 3 .
- Fig. 4 shows the effect of 6 on the voltage dependence of activation of Cav2.2 channels in HEK-Cav2.2 cells pretreated with the vehicle or the indicated compounds for 48 hours.
- the G-V curves are shown.
- the inset shows a comparison of half-activation potentials in DMSO and 50 mM 6 pretreated HEK-Cav2.2 cells (48 hours).
- Fig. 6 shows the concentration-effect curve for 14 (BTT-369). HEK-Cav2.2 cells were pretreated with various concentrations of compound 14 for 48 hours.
- the line is the fit of the data to the four-parameter logistic function.
- the apparent IC50 value is 31 pM.
- FIG. 7 shows the effect of 2 (BTT-245) and 14 (BTT369) on the voltage dependence of the steady-state inactivation of Cav2.2 channels. EK-Cav2.2 cells were pretreated with the indicated compounds for 48 hours. *** corresponds to p ⁇ 0.05.
- Figs. 8 and 9 show the effects of 2 and 14 on the voltage dependence of activation of Cav2.2 channels in HEK-Cav2.2 cells pretreated with the vehicle or the indicated compounds for 48 hours.
- Fig. 8 shows the average current-voltage relationships acquired during voltage ramps for each test group.
- Fig. 9 shows the average G-V curves for each treatment group.
- the gray vertical lines are the error bars (S.E.M.).
- Figs. 10 and 11 show acute effects of DMSO and 14 on the voltage dependence of activation of Cav2.2 channels in HEK-Cav2.2 cells.
- Fig. 10 shows the average G-V curves before and after 5-minute incubation with DMSO (p > 0.05).
- Fig. 11 shows the average G-V curves before and after 5-minute incubation with 14 (BTT-369, p ⁇ 0.01).
- the gray vertical lines are the error bars (S.E.M.). “ns” - stands for not significant.
- 6 striped bar
- 6 morphine-treated animals
- Fig. 14 shows at 4 weeks, a single bolus injection of compound 14 (0.1 mg/kg) significantly reversed mechanical hypersensitivity at both 1 and 24 h post-dosing.
- alkyl includes a chain of carbon atoms, which is optionally branched and contains from 1 to 20 carbon atoms. It is to be further understood that in certain embodiments, alkyl may be advantageously of limited length, including C 1 -C 12 , C 1 -C 10 , C 1 -C 9 , Ci-C 8 , C 1 -C 7 , Ci-Ce, C 1 -C 4 , and C 1 -C 3 .
- such particularly limited length alkyl groups including Ci-C 8 , C 1 -C 7 , Ci-Ce, C 1 -C 4 , and C 1 -C 3 and the like may be referred to as “lower alkyl.”
- Illustrative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl, hexyl, heptyl, octyl, and the like.
- “alkyl” may be combined with other groups, such as those provided above, to form a functionalized alkyl.
- a“carboxyalkyl” group By way of example, the combination of an“alkyl” group, as described herein, with a“carboxy” group may be referred to as a“carboxyalkyl” group.
- Other non-limiting examples include hydroxyalkyl, aminoalkyl, and the like.
- heteroaryl refers to a monocyclic or fused ring group of 5 to
- heteroaryl may be advantageously of limited size such as 3- to 7-membered heteroaryl, 5- to 7-membered heteroaryl, and the like. Heteroaryl may be unsubstituted or substituted as described for alkyl or as described in the various embodiments provided herein.
- heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, purinyl, tetrazolyl, triazinyl, pyrazinyl, tetrazinyl, quinazolinyl, quinoxalinyl, thienyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, benzisoxazolyl, benzisothiazolyl and carbazoloyl, and the like.
- Illustrative examples of heteroaryl groups shown in graphical representations include the following entities, in the form of properly bonded
- “hydroxy” or“hydroxyl” refers to an -OH group.
- alkoxy refers to both an -O-(alkyl) or an -O- (unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
- halo or“halogen” refers to fluorine, chlorine, bromine, or iodine.
- substituted means that the specified group or moiety bears one or more substituents.
- unsubstituted means that the specified group bears no substituents.
- substitution is meant to occur at any valency- allowed position on the system.
- “substituted” means that the specified group or moiety bears one, two, or three substituents.
- substituted means that the specified group or moiety bears one or two substituents.
- “substituted” means the specified group or moiety bears one substituent.
- “optional” or“optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
- “wherein each hydrogen atom in phenyl is independently optionally substituted by CO2H” means that a CO2H may be but need not be present on phenyl by replacement of a hydrogen atom for each CO2H group, and the description includes situations where phenyl is not substituted with the CO2H group.
- independently means that the subsequently described event or circumstance is to be read on its own relative to other similar events or circumstances.
- the use of“independently optionally” means that each instance of a hydrogen atom on the group may be substituted by another group, where the groups replacing each of the hydrogen atoms may be the same or different.
- the use of “independently” means that each of the groups can be selected from the set of possibilities separate from any other group, and the groups selected in the circumstance may be the same or different.
- the term“pharmaceutically acceptable salt” refers to those salts which counter ions which may be used in pharmaceuticals. See, generally, S.M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977, 66, 1-19.
- Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of subjects without undue toxicity, irritation, or allergic response.
- a compound described herein may possess a sufficiently acidic group, a sufficiently basic group, both types of functional groups, or more than one of each type, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
- Such salts include:
- (1) acid addition salts which can be obtained by reaction of the free base of the parent compound with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid, and perchloric acid and the like, or with organic acids such as acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methane sulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, succinic acid or malonic acid and the like; or [050] (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, trimethamine, N-methylglucamine,
- compositions are well known to those skilled in the art, and any such pharmaceutically acceptable salt may be contemplated in connection with the embodiments described herein.
- pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne- l,4-dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates,
- a pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric
- an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric
- the disclosure also relates to pharmaceutically acceptable prodrugs of the compounds of
- prodrug means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula (1) and Formula (la).
- A“pharmaceutically acceptable prodrug” is a prodrug that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in“Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
- the present disclosure also relates to pharmaceutically active metabolites of compounds of Formula (1) and Formula (la), and uses of such metabolites in the methods of the disclosure.
- a “pharmaceutically active metabolite” means a pharmacologically active product of metabolism in the body of a compound of Formula (1) and Formula (la), or salt thereof.
- Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini et al., J. Med. Chem. 1997, 40, 2011-2016; Shan et al., J. Pharm. Sci. 1997, 86 (7), 765-767; Bagshawe, Drug Dev. Res. 1995, 34, 220-230; Bodor, Adv.
- any formula depicted herein is intended to represent a compound of that structural formula as well as certain variations or forms.
- a formula given herein is intended to include a racemic form, or one or more enantiomeric, diastereomeric, or geometric isomers, or a mixture thereof.
- any formula given herein is intended to refer also to a hydrate, solvate, or polymorph of such a compound, or a mixture thereof.
- compounds depicted by a structural formula containing the symbol“ ' - r - A - r “ include both stereoisomers for the carbon atom to which the symbol“ ' LLL “ is attached, specifically both the bonds and .. mil " are encompassed by the meaning of “
- any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
- Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
- isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, n C, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, 36 Cl, and 125 I, respectively.
- Such isotopically labelled compounds are useful in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques [such as positron emission tomography (PET) or single -photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
- detection or imaging techniques such as positron emission tomography (PET) or single -photon emission computed tomography (SPECT)
- PET positron emission tomography
- SPECT single -photon emission computed tomography
- substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
- Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. [060] Any disubstituent referred to herein is meant to encompass the various attachment possibilities when more than one of such possibilities are allowed.
- disubstituent -A-B- where A 1 B, refers herein to such disubstituent with A attached to a first substituted member and B attached to a second substituted member, and it also refers to such disubstituent with A attached to the second substituted member and B attached to the first substituted member.
- compounds described herein comprise a compound of the Formula (la)
- compounds described herein comprise a compound the Formula
- R la is C(0)R 1 or phenyl wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C 4 alkyl, or heteroaryl.
- R 1 is -C 1 -C 4 alkyl-C0 2 H, -C 1 -C 4 alkyl-C(0)Ci-C 4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C 4 alkyl, or heteroaryl.
- R 1 is selected from the group consisting of (C 1 -C 4 alkyl)-C0 2 H and CO2H and tetrazole substituted phenyl. In some embodiments, R 1 is selected from the group consisting of CO2H substituted phenyl, tetrazole substituted phenyl, and (CH 2 ) 2 C0 2 H. In some embodiments, R 1 is (CH 2 ) 2 C0 2 H.
- R 2 is phenyl, heteroaryl, C 1 -C 4 alkyl-phenyl, or C 1 -C 4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with C 1 -C 4 alkoxy.
- R 2 is selected from the group consisting of phenyl, methoxy substituted phenyl, and pyridinyl.
- R 2 is phenyl, methoxy substituted phenyl, or heteroaryl.
- R 2 is phenyl.
- R 2 is methoxy substituted phenyl.
- R 3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C 1 -C 3 alkyl, halo, -C 1 -C 4 alkoxy, or heteroaryl.
- R 3 is selected from the group consisting of (C 1 -C 3 alkyl) substituted phenyl and halo substituted phenyl.
- R 3 is methyl-phenyl or chloro-phenyl.
- R 4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with C 1 -C 4 alkoxy, piperazinyl, or heteroaryl. In some embodiments, R 4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridyl. In some embodiments, R 4 is methoxy-phenyl or phenyl pyridyl.
- a compound of Formula (1) or Formula (la) is not
- compositions comprising the compounds described herein may further comprise one or more pharmaceutically-acceptable excipients.
- a pharmaceutically-acceptable excipient is a substance that is non-toxic and otherwise biologically suitable for administration to a subject. Such excipients facilitate administration of the compounds described herein and are compatible with the active ingredient. Examples of pharmaceutically-acceptable excipients include stabilizers, lubricants, surfactants, diluents, anti oxidants, binders, coloring agents, bulking agents, emulsifiers, or taste-modifying agents.
- pharmaceutical compositions according to the invention are sterile compositions. Pharmaceutical compositions may be prepared using compounding techniques known or that become available to those skilled in the art.
- compositions are also contemplated by the invention, including compositions that are in accord with national and local regulations governing such compositions.
- compositions and compounds described herein may be formulated as solutions, emulsions, suspensions, or dispersions in suitable pharmaceutical solvents or carriers, or as pills, tablets, lozenges, suppositories, sachets, dragees, granules, powders, powders for reconstitution, or capsules along with solid carriers according to conventional methods known in the art for preparation of various dosage forms.
- Pharmaceutical compositions of the invention may be administered by a suitable route of delivery, such as oral, parenteral, rectal, nasal, topical, or ocular routes, or by inhalation.
- the compositions are formulated for intravenous or oral administration.
- the compounds the invention may be provided in a solid form, such as a tablet or capsule, or as a solution, emulsion, or suspension.
- the compounds of the invention may be formulated to yield a dosage of, e.g., from about 0.1 mg to 1 g daily, or about 1 mg to 50 mg daily, or about 50 to 250 mg daily, or about 250 mg to 1 g daily.
- Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents.
- Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
- Exemplary liquid oral excipients include ethanol, glycerol, water, and the like.
- Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are exemplary disintegrating agents.
- Binding agents may include starch and gelatin.
- the lubricating agent if present, may be magnesium stearate, stearic acid, or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
- Capsules for oral administration include hard and soft gelatin capsules.
- active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent.
- Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil, such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
- Liquids for oral administration may be in the form of suspensions, solutions, emulsions, or syrups, or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
- suspending agents for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethyl
- the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
- Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
- Such forms may be presented in unit-dose form such as ampoules or disposable injection devices, in multi dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation.
- Illustrative infusion doses range from about 1 to 1000 pg/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
- inventive pharmaceutical compositions may be administered using, for example, a spray formulation also containing a suitable carrier.
- inventive compositions may be formulated for rectal administration as a suppository.
- the compounds of the present invention are preferably formulated as creams or ointments or a similar vehicle suitable for topical administration ⁇
- the inventive compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle.
- Another mode of administering the agents of the invention may utilize a patch formulation to effect transdermal delivery.
- the terms“treat” or“treatment” encompass both“preventative” and “curative” treatment.
- “Preventative” treatment is meant to indicate a postponement of development of a disease, a symptom of a disease, or medical condition, suppressing symptoms that may appear, or reducing the risk of developing or recurrence of a disease or symptom.
- “Curative” treatment includes reducing the severity of or suppressing the worsening of an existing disease, symptom, or condition.
- treatment includes ameliorating or preventing the worsening of existing disease symptoms, preventing additional symptoms from occurring, ameliorating or preventing the underlying systemic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping the symptoms of the disease or disorder.
- subject refers to a mammalian patient in need of such treatment, such as a human.
- a compound of Formula (1) or Formula (la) may be used in a method to treat a neurological disorder in a patient in need of such treatment.
- the method may comprise administering to the patient an effective amount of a compound of Formula 1 or Formula (la) or a pharmaceutically acceptable salt thereof.
- a compound of Formula (1), or Formula (la), or a pharmaceutically acceptable salt thereof, may also be used for the manufacture of a medicament for the treatment of pain.
- a compound of Formula (1) or Formula (la) or a pharmaceutically acceptable salt thereof may be used in a method to treat a neurological disorder such as pain in a mammal in need thereof.
- the method comprises administering to the mammal in need of treatment an effective amount of a compound, or a pharmaceutically acceptable salt thereof of Formula (1) or Formula (la).
- neurological disorders that may be treated with compounds of Formula (1) or Formula (la) include, but are not limited to, pain, chronic pain, diabetic neuropathy, neuropathy secondary to nerve trauma, trigeminal neuralgia, post herpetic neuralgia, cancer pain and AIDS-related neuropathy.
- a method to modulate protein-protein interaction between pore and auxiliary subunits of a voltage-gated ion channel in a nerve cell comprises contacting the nerve cell with an effective amount of the compound of Formula (1) or Formula (la) or a pharmaceutically acceptable salt thereof.
- the pore forming subunit is CaVal.
- the auxiliary subunit is Ca /b.
- the auxiliary subunit is CaV 3.
- the compounds of Formula (1) or Formula (la) are generally effective over a wide dosage range.
- dosages per day normally fall within the range of about 0.1 mg/kg to about 1.0 mg/kg of body weight.
- dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed with acceptable side effects, and therefore the above dosage range is not intended to limit the scope of the invention in any way.
- R la is C(0)R 1 or phenyl optionally substituted with one or more -CO2H, -C(0)OCi-C 4 alkyl, or heteroaryl, wherein R 1 is -C1-C4 alkyl-CCkH, -C1-C4 alkyl-C(0)Ci-C 4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl; [092] R 2 is phenyl, heteroaryl, -C 1 -C 4 alkyl-phenyl, or -C 1 -C 4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C 1 -C 4 alkoxy;
- R 3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C3 alkyl, halo, -C1-C4 alkoxy, or heteroaryl;
- R 4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy, piperazinyl, or heteroaryl;
- R 1 is selected from the group consisting of (C1-C4 alkyl)-C0 2 H, and -CO2H and tetrazole substituted phenyl;
- R 2 is selected from the group consisting of phenyl, methoxy substituted phenyl, and pyridinyl;
- R 3 is selected from the group consisting of (C 1 -C 3 alkyl) substituted phenyl and halo substituted phenyl;
- R 4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridyl;
- Clause 8 The compound or pharmaceutically acceptable salt thereof of any of the preceding clauses, wherein R 3 is methyl-phenyl or chloro-phenyl.
- Clause 10 The compound or pharmaceutically acceptable salt thereof of any of the preceding clauses that is selected from the group consisting of 4-(l'-isopropyl-5-(4- methoxyphenyl)-3'-(p-tolyl)-lH,rH-[3,4'-bipyrazol]-2(5H)-yl)-4-oxobutanoic acid, 3-(3'-(4- chlorophenyl)-5-(4-methoxyphenyl)-l'-phenyl-3, 4-dihydro- l'H,2H-[3, 4'-bipyrazole]-2- carbonyl)benzoic acid, 3-(T,5-bis(4-methoxyphenyl)-3'-(p-tolyl)-3,4-dihydro-rH,2H-[3,4'- bipyrazole]-2-carbonyl)benzoic acid, and 3-(3'-(4-methylphenyl)-5-(4-
- a pharmaceutical composition comprising a compound according to any of the preceding clauses, or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier, diluent or excipient.
- a method to treat a neurological disorder in a mammal in need thereof comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof of a compound of Formula (la)
- R la is C(0)R 1 or phenyl optionally substituted with one or more -CO2H, -C(0)OCi-C 4 alkyl, or heteroaryl, wherein R 1 is -C1-C4 alkyl-C02H, -C1-C4 alkyl-C(0)Ci-C 4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C 4 alkyl, or heteroaryl;
- R 2 is phenyl, heteroaryl, -C 1 -C 4 alkyl-phenyl, or -C 1 -C 4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C 1 -C 4 alkoxy;
- R 3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C 1 -C 3 alkyl, halo, -C 1 -C 4 alkoxy, or heteroaryl;
- R 4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy, piperazinyl, or heteroaryl;
- Clause 13 A method to treat a neurological disorder in a mammal in need thereof, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof of a compound of of Formula (1)
- R 1 is selected from the group consisting of -(C 1 -C 4 alkyl)-C0 2 H, and -CO2H and tetrazole substituted phenyl;
- R 2 is selected from the group consisting of phenyl, methoxy substituted phenyl, and pyridinyl;
- R 3 is selected from the group consisting of (C 1 -C 3 alkyl) substituted phenyl and halo substituted phenyl;
- R 4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridyl.
- Clause 14 The method of clause 12 or clause 13, wherein the neurological disorder is pain.
- Clause 15 The method of any of clauses 12-14, wherein R 1 is selected from the group consisting of CO2H substituted phenyl, tetrazole substituted phenyl, and -(CFF ⁇ CCkFl. [0129] Clause 16. The method of any of clauses 12-15, wherein R 1 is -(Ctb ⁇ CCkH.
- Clause 18 The method of any of clauses 12-17, wherein R 2 is phenyl.
- Clause 20 The method of any of clauses 12-19, wherein R 3 is methyl-phenyl or chloro- phenyl.
- Clause 21 The method of any of clauses 12-20, wherein R 4 is methoxy-phenyl or phenyl substituted with pyridyl.
- Clause 22 The method of any of clauses 12-21, wherein the compound is selected from the group consisting of 4-(T-isopropyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-lH,rH-[3,4'- bipyrazol]-2(5H)-yl)-4-oxobutanoic acid, 3-(3'-(4-chlorophenyl)-5-(4-methoxyphenyl)-T- phenyl-3,4-dihydro-l'H,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, 3-(l',5-bis(4- methoxyphenyl)-3'-(p-tolyl)-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, and 3-(3'-(4-methylphenyl)-5-(4-me
- Clause 23 A method to modulate a protein-protein interaction between pore and auxiliary subunits of a voltage-gated ion channel in a nerve cell, comprising contacting the nerve cell with an effective amount of the compound of Formula (la)
- R la is C(0)R 1 or phenyl optionally substituted with one or more -CO2H, -C(0)OCi-C 4 alkyl, or heteroaryl, wherein R 1 is -C 1 -C 4 alkyl-CCkH, -C 1 -C 4 alkyl-C(0)Ci-C 4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C 4 alkyl, or heteroaryl;
- R 2 is phenyl, heteroaryl, -C 1 -C 4 alkyl-phenyl, or -C 1 -C 4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C 1 -C 4 alkoxy;
- R 3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C3 alkyl, halo, -C1-C4 alkoxy, or heteroaryl; and [0141] R 4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy, piperazinyl, or heteroaryl;
- Clause 24 A method to modulate a protein-protein interaction between pore and auxiliary subunits of a voltage-gated ion channel in a nerve cell, comprising contacting the nerve cell with an effective amount of the compound of Formula (1)
- R 1 is selected from the group consisting of -(C1-C4 alkyl)-C0 2 H, and -CO2H and tetrazole substituted phenyl;
- R 2 is selected from the group consisting of phenyl, methoxy substituted phenyl, and pyridinyl;
- R 3 is selected from the group consisting of (C 1 -C 3 alkyl) substituted phenyl and halo substituted phenyl;
- R 4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridyl.
- Clause 25 The method of clause 23 or clause 24, wherein the pore forming subunit is CaVal.
- Clause 27 The method of any of clauses 23-26, wherein the neurological disorder is pain.
- Clause 28 The method of any of clauses 23-27, wherein R 1 is selected from the group consisting of CO2H substituted phenyl, tetrazole substituted phenyl, and -(CFF ⁇ CCkFl.
- Clause 29 The method of any of clauses 23-28, wherein R 1 is -(CFF ⁇ CCkFl.
- Clause 30 The method of any of clauses 23-29, wherein R 2 is phenyl, methoxy substituted phenyl, or heteroaryl.
- Clause 31 The method of any of clauses 23-30, wherein R 2 is phenyl.
- Clause 32 The method of any of clauses 23-31, wherein R 2 is methoxy substituted phenyl.
- Clause 33 The method of any of clauses 23-32, wherein R 3 is methyl-phenyl or chloro- phenyl.
- Clause 34 The method of any of clauses 23-33, wherein R 4 is methoxy-phenyl or phenyl substituted with pyridyl.
- Clause 35 The method of any of clauses 23-34, wherein the compound is selected from the group consisting of 4-(T-isopropyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-lH,rH-[3,4'- bipyrazol]-2(5H)-yl)-4-oxobutanoic acid, 3-(3'-(4-chlorophenyl)-5-(4-methoxyphenyl)-l'- phenyl-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, 3-(l',5-bis(4- methoxyphenyl)-3'-(p-tolyl)-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, and 3-(3'-(4-methylphenyl)-5-(4-
- Clause 37 The compound of clause 36, selected from the group consisting of
- Clause 38 Use of a compound according to any one of clauses 1-10, 36, or 37, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating a neurological disorder in a patient.
- Clause 39 The use of clause 38, wherein the neurological disorder is pain.
- Clause 40 A compound according to any one of clauses 1-10, 36, or 37, or a pharmaceutically acceptable salt thereof, for treating a neurological disorder in a patient.
- the compounds of the present invention, or salts thereof may be prepared by a variety of procedures known to one of ordinary skill in the art, some of which are illustrated in the schemes, preparations, and examples below.
- One of ordinary skill in the art recognizes that the specific synthetic steps for each of the routes described may be combined in different ways, or in conjunction with steps from different schemes, to prepare compounds of the invention, or salts thereof.
- the products of each step in the schemes below can be recovered by conventional methods well known in the art, including extraction, evaporation, precipitation, chromatography, filtration, trituration, and crystallization. In the schemes below, all substituents unless otherwise indicated, are as previously defined.
- the reagents and starting materials are readily available to one of ordinary skill in the art.
- a compound of Formula 1 can be prepared in accordance with reactions as depicted in Scheme 1.
- intermediate compound la can be synthesized from phenylhydrazine and 4’-methylacetophenone by simple condensation (step a).
- Intermediate la can be stored in darkness, under argon gas at 4°C.
- Excess Vilsmeier reagent (DMF+POCF) can be added to intermediate la to generate intermediate lb (step b).
- Condensation with substituted acetophenones yields the intermediate enone lc (step c).
- Subsequent coupling with excess hydrazine hydride yields the second 4,5- dihydropyrazole ring in intermediate compound ld (step d).
- An amidation can be carried out using anhydrous pyridine to generate intermediate le (step e).
- Hydrolysis using 2 M LiOH aqueous solution in methanol/THF co-solvents at r.t. results in compound 1 (step f).
- Scheme 2 depicts a route for synthesizing compound 3. fir
- Scheme 3 depicts a route for synthesizing compound 4.
- Scheme 4 depicts a route for synthesizing compound 11.
- Scheme 5 depicts a route for synthesizing compound 14.
- Scheme 5 depicts a route for synthesizing compound 15.
- the His-Cav 3 protein was purified at 4 °C using Ni-IMAC chromatography (His-Trap HP, GE Healthcare) and eluted with 500 mM imidazole in lysis buffer with a gradient method. After the fractions consisted of His-Cav 3 was combined and concentrated, the protein was further purified using size exclusion chromatography (Superdex 200 pg, GE Healthcare) in PBS with 2 mM DTT.
- Compound 6 forms a salt bridge interaction with Arg-307 through a benzoic acid moiety.
- Arg-307 was mutated to alanine.
- the resulting Cav 3 Arg-307- Ala mutant binds to CaVal- AiD with a Kd of 240 ⁇ 59 nM, a nearly lO-fold reduction.
- HEKCav2.2 cells were treated with compound 6 or the vehicle (DMSO) for 48 hours.
- the surface proteins were biotinylated with 5 mM biotin-X-NHS (EMD Millipore, Billerica, MA) in
- the eluted proteins were separated using 10% SDS-polyacrylamide gel electrophoresis, transferred onto polyvinylidene difluoride membrane (PVDF) (Immun-Blot, Bio-Rad), and probed with the anti-Cav2.2-alB antibody from Alomone Labs (1:1000 dilution; Israel, Cat. #: AC002) and the Na+, K+-ATPase antibody (1:1000 dilution; Cell Signaling, Cat.#30l0).
- PVDF polyvinylidene difluoride membrane
- HEK293 cells that stably expressed rat N-type CaV2.2alB, rat CaV 3, and rat a2d-1 were utilized.
- Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 50 units penicillin, 50 pg/ml streptomycin, 5 pg/ml blasticidin, 5 pg/ml hydromycin and 25 pg/ml zeozin at 37 °C in a humidified atmosphere of 95% air and 5% C0 2 .
- DMEM Dulbecco’s modified Eagle’s medium
- HEK-Cav2.2 cells were plated on glass coverslips and were cultured for 24-48 h. All animal procedures were performed in accordance to the NIH guide and were approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee. Young adult Sprague Dawley rats were anesthetized (3% isoflurane) and then decapitated. The spinal column was removed, cut open, and dorsal root ganglia were harvested from the Lumbar L4-L6 vertebral levels.
- the ganglia were incubated in DMEM containing collagenase (1 mg/ml, Worthington: LS04194) and protease (1 mg/ml, Worthington: LS02104) for 30-60 minutes, and DRG neurons were dissociated by triturating in DMEM supplemented with 10% FBS.
- the isolated DRG neurons were plated on glass coverslips coated with growth factor reduced Matrigel (Thermo Fisher Scientific, Waltham, MA) and were cultured in Eagle's minimum essential medium (Invitrogen, CA) supplemented with 0.2% BSA and 20 ng/ml NGF-2.5S (BD Biosciences, Bedford, MA) at 37°C in a water- jacketed 5% CO2 incubator overnight for the patch-clamp experiments.
- G-V curves for CaV2.2 were shifted towards more positive potentials in HEK-Cav2.2 cells pretreated with compound 6 for 48 hours.
- inventive compounds were freshly prepared saline (0.9%) on the day of the experiment.
- Morphine sulfate salt Sigma- Aldrich, St. Louis, MO was freshly prepared on the day of the experiment in saline. All drugs were dissolved in 1 mL solution and administered by intraperitoneal (i.p.) injections 1 h prior to all behavioral assays.
- Plasma concentrations at various time points were determined using liquid chromatography tandem mass spectroscopy (LC-MS/MS).
- IV intravenous
- compound 14 was formulated as a solution at a final dose of 1 mg/kg.
- the elimination half-life of compound 14 was 0.29 hours.
- the Tmax in plasma was 0.083 hours, and the Cmax peak plasma concentration was 181.36 ng/ml.
- the AUC 0-t concentration was 57.99 ng/ml*h.
- compound 14 was formulated as a solution at a final dose of 10 mg/kg. Plasma concentrations at various time points were determined using LC-MS/MS. The elimination half-life of compound 14 was 1.99 hours. The Tmax in plasma was 1 hour, and the Cmax peak plasma concentration was 164.7 ng/ml. The AUC 0-t concentration was 635.555 ng/ml*h.
- the inventive compounds were assessed with the tibial nerve injury (TNI) model of neuropathic pain 28 days after surgery. Using isoflurane anesthesia (4% induction and 2% maintenance), the right sciatic nerve was isolated under aseptic surgical conditions by blunt dissection of the femoral biceps muscle and the tibial nerve was tightly ligated with 5-0 silk and transected distal to the ligation. Additional 2 to 3 mm of distal nerve stump was removed to prevent reinnervation by the proximal nerve. The overlying muscle and skin was then sutured in 2 separate layers. Sham-injured animals were subjected to all preceding procedures with the exception of ligation and transection.
- TPI tibial nerve injury
- PK profiles of compound 14 after intravenous and oral administration was performed in Kunming mice. Plasma concentrations were determined by liquid chromatography tandem mass spectroscopy. Summary of PK properties and plasma concentration measured 1 hour after intravenous or oral administration of 1 or 10 mg/kg compound 14.
Abstract
This invention relates to pyrazolylacylpyrazoline compounds or pharmaceutically acceptable salts thereof, and for the use of the compounds to treat neurological disorders.
Description
PYRAZOLYLACYLPYRAZOLINE COMPOUNDS AND METHOD FOR TREATING PAIN
CROSS-REFERENCE TO RELATED APPLICATIONS
[001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 62/733,153, filed on September 19, 2018, the entire disclosure of which is incorporated herein by reference
GOVERNMENT RIGHTS
[002] This invention was made with government support under HL115140 and TR001108 awarded by National Institutes of Health. The government has certain rights in the invention.
BACKGROUND
[003] In the central nervous system, voltage-gated calcium channels play important and diverse roles in the synaptic transmission of electrical signals (e.g., neurotransmitter release), in the integration and modulation of these signals, and in the transduction of membrane depolarization into intracellular signals. To accomplish these diverse functions, neurons express a variety of calcium channels that are composed of large heteromeric assemblies of pore forming al (CaVal) subunits and auxiliary subunits. Among the auxiliary subunits of voltage-gated calcium channels, CaV increase the surface expression of voltage-gated calcium channels and regulate their biophysical properties. The interaction between pore and auxiliary subunits is driven by protein-protein interactions. One such interaction between pore and auxiliary subunits of a voltage-gated ion channel is a tight CaVaDCaV protein-protein interaction.
[004] Pain is a prevalent problem. Pain can arise from or accompany a wide variety of diseases and disease states. Clinically-approved blockers of voltage-gated calcium channels for pain management are encumbered by numerous off-target effects and exhibit narrow therapeutic windows. A need remains for compounds to treat pain that are both non- addictive and avoid the other drawbacks of existing pain medicines.
SUMMARY
[005] In one aspect, the disclosure relates to a compound of the Formula (1)
[006] wherein R1 is selected from the group consisting of -(C1-C4 alkyl)-C02H, -CO2H and tetrazole substituted phenyl; R2 is selected from the group consisting of phenyl, methoxy substituted phenyl and pyridinyl; R3 is selected from the group consisting of (C1-C3 alkyl) substituted phenyl halo substituted phenyl; and R4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridine; or a pharmaceutically acceptable salt thereof.
[007] In another aspect, the disclosure relates to a compound of the Formula (la)
[008] wherein
[009] Rla is C(0)R1 or phenyl optionally substituted with one or more -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl, wherein R1 is -C1-C4 alkyl-C02H, -C1-C4 alkyl-C(0)Ci-C4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl;
[010] R2 is phenyl, heteroaryl, -C1-C4 alkyl-phenyl, or -C1-C4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy;
[Oil] R3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C3 alkyl, halo, -C1-C4 alkoxy, or heteroaryl; and
[012] R4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with C1-C4 alkoxy, piperazinyl, or heteroaryl;
[014] or a pharmaceutically acceptable salt thereof.
[015] In another aspect, the disclosure relates to a pharmaceutical composition comprising a compound of Formula (1) or Formula (la) , or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier, diluent or excipient.
[016] In another aspect, the disclosure relates a method to treat a neurological disorder in a mammal in need thereof, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof of a compound of Formula (1) or Formula (la).
[017] In another aspect, the disclosure relates to a method to modulate a protein-protein interaction between pore and auxiliary subunits of a voltage-gated ion channel in a nerve cell, comprising contacting the nerve cell with an effective amount of the compound of Formula (1) or Formula (la).
[018] Additional embodiments, features, and advantages of the disclosure will be apparent from the following detailed description and through practice of the disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
[019] Fig. 1 shows a fluorescence polarization assay used to determine an inhibition constant for compounds 6 and 14.
[020] Fig. 2 shows a binding curve that emerged from the use of microscale thermophoresis to establish direct binding of compound 6. Curve fitting analysis led to a dissociation constant of 3.6 ± 1.1 mM.
[021] Fig. 3 shows compound 6 does not inhibit the protein-protein interaction between Cav 3 Arg-307-Ala as evidenced by a lack of displacement of fluorescently-labeled Cavai-AiD bound to the mutated Cav 3.
[022] Fig. 4 shows the effect of 6 on the voltage dependence of activation of Cav2.2 channels in HEK-Cav2.2 cells pretreated with the vehicle or the indicated compounds for 48 hours. The G-V curves are shown. The inset shows a comparison of half-activation potentials in DMSO and 50 mM 6 pretreated HEK-Cav2.2 cells (48 hours).
[023] Fig. 5 shows the Cav2.2 current densities in HEK-Cav2.2 cells pretreated for 48 hours with either DMSO (n = 15), 14 (BTT-369, n = 12), or 2 (BTT-245, n = 9). *** corresponds to p < 0.001.
[024] Fig. 6 shows the concentration-effect curve for 14 (BTT-369). HEK-Cav2.2 cells were pretreated with various concentrations of compound 14 for 48 hours. Cav2.2 currents were acquired during 20-ms depolarizing pulses, and the current densities were calculated as a ratio of the peak current amplitude and each cell capacitance (0.1 mM, n = 6; 1 mM, n = 7; 10 pM, n = 8; 50 pM, n = 12). The line is the fit of the data to the four-parameter logistic function. The apparent IC50 value is 31 pM.
[025] Fig. 7 shows the effect of 2 (BTT-245) and 14 (BTT369) on the voltage dependence of the steady-state inactivation of Cav2.2 channels. EK-Cav2.2 cells were pretreated with the indicated compounds for 48 hours. *** corresponds to p < 0.05.
[026] Figs. 8 and 9 show the effects of 2 and 14 on the voltage dependence of activation of Cav2.2 channels in HEK-Cav2.2 cells pretreated with the vehicle or the indicated compounds for 48 hours. Fig. 8 shows the average current-voltage relationships acquired during voltage ramps for each test group. Fig. 9 shows the average G-V curves for each treatment group. The gray vertical lines are the error bars (S.E.M.).
[027] Figs. 10 and 11 show acute effects of DMSO and 14 on the voltage dependence of activation of Cav2.2 channels in HEK-Cav2.2 cells. Fig. 10 shows the average G-V curves before and after 5-minute incubation with DMSO (p > 0.05). Fig. 11 shows the average G-V curves before and after 5-minute incubation with 14 (BTT-369, p < 0.01). The gray vertical lines are the error bars (S.E.M.). “ns” - stands for not significant.
[028] Fig. 12 shows a bar graph of paw withdrawal latency (PWL, in seconds) of rats (n = 6 per group) demonstrating a lack of analgesic effect for compound 2 or 6.
[029] Fig. 13 shows withdrawal threshold (in milli-Newtons, mN) in response to von Frey stimulation to the paw ipsilateral to injury following a single, intraperitoneal administration of vehicle, morphine (5 mg/kg), compound 2, or compound 6 (10 mg/kg, n = 8) at 4 weeks after TNI. The ability of 6 (striped bar) to reverse TNI-induced mechanical hypersensitivity was significantly different from both 2 (solid grey bar) and morphine-treated animals (black striped bar). (*p < 0.05 versus 2 and morphine-treated TNI rodents (mean ± SE; n = 8, repeated measures ANOVA with Tukey post-hoc).
[030] Fig. 14 shows at 4 weeks, a single bolus injection of compound 14 (0.1 mg/kg) significantly reversed mechanical hypersensitivity at both 1 and 24 h post-dosing. For comparison, 6 (10 mg/kg) reversal of mechanical hypersensitivity was limited to 1 h (*p < 0.05 versus 6 and vehicle-treated TNI rodents (mean ± SE; n = 8, repeated measures ANOVA with Tukey post-hoc).
DETAILED DESCRIPTION
[031] Before the present disclosure is further described, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
[032] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications and other publications referred to herein are incorporated by reference in their entireties. If a definition set forth in this section is contrary to or otherwise inconsistent with a definition set forth in a patent, application, or other publication that is herein incorporated by reference, the definition set forth in this section prevails over the definition incorporated herein by reference.
[033] As used herein and in the appended claims, the singular forms“a,”“an,” and“the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as“solely,”“only” and the like in connection with the recitation of claim elements, or use of a“negative” limitation.
[034] As used herein, the terms“including,”“containing,” and“comprising” are used in their open, non-limiting sense.
[035] To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term“about.” It is understood that, whether the term“about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and/or measurement conditions for such given value. Whenever a yield is given as a percentage, such yield refers to a mass of the entity for which the yield is given with respect to the maximum amount of the same entity that could be obtained under the particular stoichiometric conditions. Concentrations that are given as percentages refer to mass ratios, unless indicated differently.
[036] Except as otherwise noted, the methods and techniques of the present embodiments are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See, e.g., Loudon, Organic Chemistry, Fourth Edition, New York:
Oxford University Press, 2002, pp. 360-361, 1084-1085; Smith and March, March's Advanced
Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience,
2001.
[037] Chemical nomenclature for compounds described herein has generally been derived using the commercially-available ACD/Name 2014 (ACD/Labs) or ChemBioDraw ultra 13.0 (Perkin Elmer).
[038] It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the disclosure, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. All combinations of the embodiments pertaining to the chemical groups represented by the variables are specifically embraced by the present disclosure and are disclosed herein just as if each and every combination was individually and explicitly disclosed, to the extent that such combinations embrace compounds that are stable compounds (i.e., compounds that can be isolated, characterized, and tested for biological activity). In addition, all subcombinations of the chemical groups listed in the embodiments describing such variables are also specifically embraced by the present disclosure and are disclosed herein just as if each and every such sub-combination of chemical groups was individually and explicitly disclosed herein.
Definitions
[039] As used herein, the term“alkyl” includes a chain of carbon atoms, which is optionally branched and contains from 1 to 20 carbon atoms. It is to be further understood that in certain embodiments, alkyl may be advantageously of limited length, including C1-C12, C1-C10, C1-C9, Ci-C8, C1-C7, Ci-Ce, C1-C4, and C1-C3. Illustratively, such particularly limited length alkyl groups, including Ci-C8, C1-C7, Ci-Ce, C1-C4, and C1-C3 and the like may be referred to as “lower alkyl.” Illustrative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl, hexyl, heptyl, octyl, and the like. It will be understood that“alkyl” may be combined with other groups, such as those provided above, to form a functionalized alkyl. By way of example, the combination of an“alkyl” group, as described herein, with a“carboxy” group may be referred to as a“carboxyalkyl” group. Other non-limiting examples include hydroxyalkyl, aminoalkyl, and the like.
[040] As used herein, the term“heteroaryl” refers to a monocyclic or fused ring group of 5 to
12 ring atoms containing one, two, three or four ring heteroatoms selected from nitrogen, oxygen and sulfur, the remaining ring atoms being carbon atoms, and also having a completely
conjugated pi-electron system. It will be understood that in certain embodiments, heteroaryl may be advantageously of limited size such as 3- to 7-membered heteroaryl, 5- to 7-membered heteroaryl, and the like. Heteroaryl may be unsubstituted or substituted as described for alkyl or as described in the various embodiments provided herein. Illustrative heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, purinyl, tetrazolyl, triazinyl, pyrazinyl, tetrazinyl, quinazolinyl, quinoxalinyl, thienyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, benzisoxazolyl, benzisothiazolyl and carbazoloyl, and the like. Illustrative examples of heteroaryl groups shown in graphical representations, include the following entities, in the form of properly bonded moieties:
[041] As used herein,“hydroxy” or“hydroxyl” refers to an -OH group.
[042] As used herein,“alkoxy” refers to both an -O-(alkyl) or an -O- (unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[043] As used herein,“halo” or“halogen” refers to fluorine, chlorine, bromine, or iodine.
[044] As used herein,“bond” refers to a covalent bond.
[045] The term“substituted” means that the specified group or moiety bears one or more substituents. The term“unsubstituted” means that the specified group bears no substituents. Where the term“substituted” is used to describe a structural system, the substitution is meant to occur at any valency- allowed position on the system. In some embodiments,“substituted” means that the specified group or moiety bears one, two, or three substituents. In other
embodiments, “substituted” means that the specified group or moiety bears one or two substituents. In still other embodiments,“substituted” means the specified group or moiety bears one substituent.
[046] As used herein,“optional” or“optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example,“wherein each hydrogen atom in phenyl is independently optionally substituted by CO2H” means that a CO2H may be but need not be present on phenyl by replacement of a hydrogen atom for each CO2H group, and the description includes situations where phenyl is not substituted with the CO2H group.
[047] As used herein, “independently” means that the subsequently described event or circumstance is to be read on its own relative to other similar events or circumstances. For example, in a circumstance where several equivalent hydrogen groups are optionally substituted by another group described in the circumstance, the use of“independently optionally” means that each instance of a hydrogen atom on the group may be substituted by another group, where the groups replacing each of the hydrogen atoms may be the same or different. Or for example, where multiple groups exist all of which can be selected from a set of possibilities, the use of “independently” means that each of the groups can be selected from the set of possibilities separate from any other group, and the groups selected in the circumstance may be the same or different.
[048] As used herein, the term“pharmaceutically acceptable salt” refers to those salts which counter ions which may be used in pharmaceuticals. See, generally, S.M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977, 66, 1-19. Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of subjects without undue toxicity, irritation, or allergic response. A compound described herein may possess a sufficiently acidic group, a sufficiently basic group, both types of functional groups, or more than one of each type, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. Such salts include:
[049] (1) acid addition salts, which can be obtained by reaction of the free base of the parent compound with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid, and perchloric acid and the like, or with organic acids such as acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methane sulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, succinic acid or malonic acid and the like; or
[050] (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, trimethamine, N-methylglucamine, and the like.
[051] Pharmaceutically acceptable salts are well known to those skilled in the art, and any such pharmaceutically acceptable salt may be contemplated in connection with the embodiments described herein. Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne- l,4-dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methylsulfonates, propylsulfonates, besylates, xylenesulfonates, naphthalene- 1- sulfonates, naphthalene-2-sulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, g-hydroxybutyrates, glycolates, tartrates, and mandelates. Lists of other suitable pharmaceutically acceptable salts are found in Remington's Pharmaceutical Sciences, l7th Edition, Mack Publishing Company, Easton, Pa., 1985.
[052] For a compound of Formula (1) or Formula (la) that contains a basic nitrogen, a pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a sulfonic acid, such as laurylsulfonic acid, p- toluenesulfonic acid, methanesulfonic acid, or ethanesulfonic acid, or any compatible mixture of acids such as those given as examples herein, and any other acid and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
[053] The disclosure also relates to pharmaceutically acceptable prodrugs of the compounds of
Formula (1) and Formula (la) and treatment methods employing such pharmaceutically
acceptable prodrugs. The term“prodrug” means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula (1) and Formula (la). A“pharmaceutically acceptable prodrug” is a prodrug that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in“Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
[054] The present disclosure also relates to pharmaceutically active metabolites of compounds of Formula (1) and Formula (la), and uses of such metabolites in the methods of the disclosure. A “pharmaceutically active metabolite” means a pharmacologically active product of metabolism in the body of a compound of Formula (1) and Formula (la), or salt thereof. Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini et al., J. Med. Chem. 1997, 40, 2011-2016; Shan et al., J. Pharm. Sci. 1997, 86 (7), 765-767; Bagshawe, Drug Dev. Res. 1995, 34, 220-230; Bodor, Adv. Drug Res. 1984, 13, 255-331; Bundgaard, Design of Prodrugs (Elsevier Press, 1985); and Larsen, Design and Application of Prodrugs, Drug Design and Development (Krogsgaard-Larsen et al., eds., Harwood Academic Publishers, 1991).
[055] Any formula depicted herein is intended to represent a compound of that structural formula as well as certain variations or forms. For example, a formula given herein is intended to include a racemic form, or one or more enantiomeric, diastereomeric, or geometric isomers, or a mixture thereof. Additionally, any formula given herein is intended to refer also to a hydrate, solvate, or polymorph of such a compound, or a mixture thereof. For example, it will be appreciated that compounds depicted by a structural formula containing the symbol“ '-r-A-r “ include both stereoisomers for the carbon atom to which the symbol“ 'LLL“ is attached, specifically both the bonds
and .. mil " are encompassed by the meaning of “
'rv-r-r “. For example, in some exemplary embodiments, certain compounds provided herein can be described by the formula
[056] which formula will be understood to encompass compounds having both stereochemical configurations at the relevant carbon atom, specifically in this example
and other stereochemical combinations.
[057] Compounds of Formula (1) and Formula (la) wherein the chiral center at the core pyrazoline ring are in the S- configuration are further preferred. Although the present invention contemplates all individual enantiomers and diastereomers, as well as mixtures of the enantiomers of the compounds, including racemates, the compounds with the absolute configuration as set forth below are particularly preferred.
[058] Individual isomers, enantiomers, and diastereomers may be separated or resolved by one of ordinary skill in the art at any convenient point in the synthesis of compounds of the invention, by methods such as selective crystallization techniques or chiral chromatography (See for example, J. Jacques, et al.,“Enantiomers, Racemates, and Resolutions”, John Wiley and Sons, Inc., 1981, and E.L. Eliel and S.H. Wilen,” Stereochemistry of Organic Compounds”, Wiley-Interscience, 1994).
[059] Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2H, 3H, nC, 13C, 14C, 15N, 180, 170, 31P, 32P, 35S, 18F, 36Cl, and 125I, respectively. Such isotopically labelled compounds are useful in metabolic studies (preferably with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques [such as positron emission tomography (PET) or single -photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
[060] Any disubstituent referred to herein is meant to encompass the various attachment possibilities when more than one of such possibilities are allowed. For example, reference to disubstituent -A-B-, where A ¹ B, refers herein to such disubstituent with A attached to a first substituted member and B attached to a second substituted member, and it also refers to such disubstituent with A attached to the second substituted member and B attached to the first substituted member.
REPRESENTATIVE EMBODIMENTS
[061] In some embodiments, compounds described herein comprise a compound of the Formula (la)
[062] or a pharmaceutical acceptable salt thereof.
[063] In some embodiments, compounds described herein comprise a compound the Formula
(1)
[064] or a pharmaceutical acceptable salt thereof.
[065] In some embodiments, Rla is C(0)R1 or phenyl wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl. In some embodiments, R1 is -C1-C4 alkyl-C02H, -C1-C4 alkyl-C(0)Ci-C4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl. In some embodiments, R1 is selected from the group consisting of (C1-C4 alkyl)-C02H and CO2H and tetrazole substituted phenyl. In some
embodiments, R1 is selected from the group consisting of CO2H substituted phenyl, tetrazole substituted phenyl, and (CH2)2C02H. In some embodiments, R1 is (CH2)2C02H.
[066] In some embodiments, R2 is phenyl, heteroaryl, C1-C4 alkyl-phenyl, or C1-C4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with C1-C4 alkoxy. In some embodiments, R2 is selected from the group consisting of phenyl, methoxy substituted phenyl, and pyridinyl. In some embodiments, R2 is phenyl, methoxy substituted phenyl, or heteroaryl. In some embodiments, R2 is phenyl. In some embodiments, R2 is methoxy substituted phenyl.
[067] In some embodiments, R3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C3 alkyl, halo, -C1-C4 alkoxy, or heteroaryl. In some embodiments, R3 is selected from the group consisting of (C1-C3 alkyl) substituted phenyl and halo substituted phenyl. In some embodiments, R3 is methyl-phenyl or chloro-phenyl.
[068] In some embodiments, R4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with C1-C4 alkoxy, piperazinyl, or heteroaryl. In some embodiments, R4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridyl. In some embodiments, R4 is methoxy-phenyl or phenyl pyridyl.
[069] In some illustrative embodiments, a compound of Formula (1) or Formula (la) is not
[070] The following represent illustrative embodiments of compounds of the Formula (1) and Formula (la):
[071] Those skilled in the art will recognize that the species listed or illustrated herein are not exhaustive, and that additional species within the scope of these defined terms may be selected.
PHARMACEUTICAL COMPOSITIONS
[072] For treatment purposes, pharmaceutical compositions comprising the compounds described herein may further comprise one or more pharmaceutically-acceptable excipients. A pharmaceutically-acceptable excipient is a substance that is non-toxic and otherwise biologically suitable for administration to a subject. Such excipients facilitate administration of the compounds described herein and are compatible with the active ingredient. Examples of pharmaceutically-acceptable excipients include stabilizers, lubricants, surfactants, diluents, anti oxidants, binders, coloring agents, bulking agents, emulsifiers, or taste-modifying agents. In preferred embodiments, pharmaceutical compositions according to the invention are sterile compositions. Pharmaceutical compositions may be prepared using compounding techniques known or that become available to those skilled in the art.
[073] Sterile compositions are also contemplated by the invention, including compositions that are in accord with national and local regulations governing such compositions.
[074] The pharmaceutical compositions and compounds described herein may be formulated as solutions, emulsions, suspensions, or dispersions in suitable pharmaceutical solvents or carriers, or as pills, tablets, lozenges, suppositories, sachets, dragees, granules, powders, powders for reconstitution, or capsules along with solid carriers according to conventional methods known in the art for preparation of various dosage forms. Pharmaceutical compositions of the invention may be administered by a suitable route of delivery, such as oral,
parenteral, rectal, nasal, topical, or ocular routes, or by inhalation. Preferably, the compositions are formulated for intravenous or oral administration.
[075] For oral administration, the compounds the invention may be provided in a solid form, such as a tablet or capsule, or as a solution, emulsion, or suspension. To prepare the oral compositions, the compounds of the invention may be formulated to yield a dosage of, e.g., from about 0.1 mg to 1 g daily, or about 1 mg to 50 mg daily, or about 50 to 250 mg daily, or about 250 mg to 1 g daily. Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like. Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are exemplary disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid, or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
[076] Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil, such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
[077] Liquids for oral administration may be in the form of suspensions, solutions, emulsions, or syrups, or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
[078] For parenteral use, including intravenous, intramuscular, intraperitoneal, intranasal, or subcutaneous routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms may be presented in unit-dose form such as ampoules or disposable injection devices, in multi dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses range from about 1 to 1000 pg/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
[079] For nasal, inhaled, or oral administration, the inventive pharmaceutical compositions may be administered using, for example, a spray formulation also containing a suitable carrier. The inventive compositions may be formulated for rectal administration as a suppository.
[080] For topical applications, the compounds of the present invention are preferably formulated as creams or ointments or a similar vehicle suitable for topical administration· For topical administration, the inventive compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle. Another mode of administering the agents of the invention may utilize a patch formulation to effect transdermal delivery.
[081] As used herein, the terms“treat” or“treatment” encompass both“preventative” and “curative” treatment. “Preventative” treatment is meant to indicate a postponement of development of a disease, a symptom of a disease, or medical condition, suppressing symptoms that may appear, or reducing the risk of developing or recurrence of a disease or symptom. “Curative” treatment includes reducing the severity of or suppressing the worsening of an existing disease, symptom, or condition. Thus, treatment includes ameliorating or preventing the worsening of existing disease symptoms, preventing additional symptoms from occurring, ameliorating or preventing the underlying systemic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping the symptoms of the disease or disorder.
[082] The term“subject” refers to a mammalian patient in need of such treatment, such as a human.
[083] A compound of Formula (1) or Formula (la) may be used in a method to treat a neurological disorder in a patient in need of such treatment. Illustratively, the method may comprise administering to the patient an effective amount of a compound of Formula 1 or Formula (la) or a pharmaceutically acceptable salt thereof.
[084] A compound of Formula (1), or Formula (la), or a pharmaceutically acceptable salt thereof, may also be used for the manufacture of a medicament for the treatment of pain.
[085] In some embodiments, a compound of Formula (1) or Formula (la) or a pharmaceutically acceptable salt thereof may be used in a method to treat a neurological
disorder such as pain in a mammal in need thereof. The method comprises administering to the mammal in need of treatment an effective amount of a compound, or a pharmaceutically acceptable salt thereof of Formula (1) or Formula (la). In some embodiments, neurological disorders that may be treated with compounds of Formula (1) or Formula (la) include, but are not limited to, pain, chronic pain, diabetic neuropathy, neuropathy secondary to nerve trauma, trigeminal neuralgia, post herpetic neuralgia, cancer pain and AIDS-related neuropathy.
[086] In some embodiments, a method to modulate protein-protein interaction between pore and auxiliary subunits of a voltage-gated ion channel in a nerve cell, comprises contacting the nerve cell with an effective amount of the compound of Formula (1) or Formula (la) or a pharmaceutically acceptable salt thereof. In one embodiment, the pore forming subunit is CaVal. In another embodiment, the auxiliary subunit is Ca /b. In another embodiment, the auxiliary subunit is CaV 3.
[087] In illustrative embodiments, the compounds of Formula (1) or Formula (la) are generally effective over a wide dosage range. For example, dosages per day normally fall within the range of about 0.1 mg/kg to about 1.0 mg/kg of body weight. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed with acceptable side effects, and therefore the above dosage range is not intended to limit the scope of the invention in any way.
[088] The compounds of the present disclosure can be described as embodiments in any of the following enumerated clauses. It will be understood that any of the embodiments described herein can be used in connection with any other embodiments described herein to the extent that the embodiments do not contradict one another.
[089] Clause 1. A compound of Formula (la)
[090] wherein
[091] Rla is C(0)R1 or phenyl optionally substituted with one or more -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl, wherein R1 is -C1-C4 alkyl-CCkH, -C1-C4 alkyl-C(0)Ci-C4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl;
[092] R2 is phenyl, heteroaryl, -C1-C4 alkyl-phenyl, or -C1-C4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy;
[093] R3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C3 alkyl, halo, -C1-C4 alkoxy, or heteroaryl; and
[094] R4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy, piperazinyl, or heteroaryl;
[095] with the proviso that the compound of Formula (la) is not
[096] or a pharmaceutically acceptable salt thereof.
[097] Clause 2. A compound of Formula (1)
[098] wherein
[099] R1 is selected from the group consisting of (C1-C4 alkyl)-C02H, and -CO2H and tetrazole substituted phenyl;
[0100] R2 is selected from the group consisting of phenyl, methoxy substituted phenyl, and pyridinyl;
[0101] R3 is selected from the group consisting of (C1-C3 alkyl) substituted phenyl and halo substituted phenyl; and
[0102] R4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridyl;
[0103] with the proviso that the compound of Formula (1) is not
[0105] Clause 3. The compound or pharmaceutically acceptable salt thereof of any of the preceding clauses, wherein R1 is selected from the group consisting of -CO2H substituted phenyl, tetrazole substituted phenyl, and -(CH2)2C02H.
[0106] Clause 4. The compound or pharmaceutically acceptable salt thereof of any of the preceding clauses, wherein R1 is -(CH2)2C02H.
[0107] Clause 5. The compound or pharmaceutically acceptable salt thereof of any of the preceding clauses, wherein R2 is phenyl, methoxy substituted phenyl, or heteroaryl.
[0108] Clause 6. The compound or pharmaceutically acceptable salt thereof of any of the preceding clauses, wherein R2 is phenyl.
[0109] Clause 7. The compound or pharmaceutically acceptable salt thereof of any of the preceding clauses, wherein R2 is methoxy substituted phenyl.
[0110] Clause 8. The compound or pharmaceutically acceptable salt thereof of any of the preceding clauses, wherein R3 is methyl-phenyl or chloro-phenyl.
[0111] Clause 9. The compound or pharmaceutically acceptable salt thereof of any of the preceding clauses, wherein R4 is methoxy-phenyl or phenyl pyridyl.
[0112] Clause 10. The compound or pharmaceutically acceptable salt thereof of any of the preceding clauses that is selected from the group consisting of 4-(l'-isopropyl-5-(4- methoxyphenyl)-3'-(p-tolyl)-lH,rH-[3,4'-bipyrazol]-2(5H)-yl)-4-oxobutanoic acid, 3-(3'-(4- chlorophenyl)-5-(4-methoxyphenyl)-l'-phenyl-3, 4-dihydro- l'H,2H-[3, 4'-bipyrazole]-2- carbonyl)benzoic acid, 3-(T,5-bis(4-methoxyphenyl)-3'-(p-tolyl)-3,4-dihydro-rH,2H-[3,4'- bipyrazole]-2-carbonyl)benzoic acid, and 3-(3'-(4-methylphenyl)-5-(4-methoxyphenyl)-T- phenyl-3 ,4-dihydro- 1 Ή,2H- [3 ,4'-bipyrazole] -2-tetrazole.
[0113] Clause 11. A pharmaceutical composition comprising a compound according to any of the preceding clauses, or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier, diluent or excipient.
[0114] Clause 12. A method to treat a neurological disorder in a mammal in need thereof, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof of a compound of Formula (la)
[0115] wherein
[0116] Rla is C(0)R1 or phenyl optionally substituted with one or more -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl, wherein R1 is -C1-C4 alkyl-C02H, -C1-C4 alkyl-C(0)Ci-C4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl;
[0117] R2 is phenyl, heteroaryl, -C1-C4 alkyl-phenyl, or -C1-C4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy;
[0118] R3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C3 alkyl, halo, -C1-C4 alkoxy, or heteroaryl; and
[0119] R4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy, piperazinyl, or heteroaryl;
[0120] or a pharmaceutically acceptable salt thereof.
[0121] Clause 13. A method to treat a neurological disorder in a mammal in need thereof, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof of a compound of of Formula (1)
[0122] wherein
[0123] R1 is selected from the group consisting of -(C1-C4 alkyl)-C02H, and -CO2H and tetrazole substituted phenyl;
[0124] R2 is selected from the group consisting of phenyl, methoxy substituted phenyl, and pyridinyl;
[0125] R3 is selected from the group consisting of (C1-C3 alkyl) substituted phenyl and halo substituted phenyl; and
[0126] R4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridyl.
[0127] Clause 14. The method of clause 12 or clause 13, wherein the neurological disorder is pain.
[0128] Clause 15. The method of any of clauses 12-14, wherein R1 is selected from the group consisting of CO2H substituted phenyl, tetrazole substituted phenyl, and -(CFF^CCkFl.
[0129] Clause 16. The method of any of clauses 12-15, wherein R1 is -(Ctb^CCkH.
[0130] Clause 17. The method of any of clauses 12-16, wherein R2 is phenyl, methoxy substituted phenyl, or heteroaryl.
[0131] Clause 18. The method of any of clauses 12-17, wherein R2 is phenyl.
[0132] Clause 19. The method of any of clauses 12-18, wherein R2 is methoxy substituted phenyl.
[0133] Clause 20. The method of any of clauses 12-19, wherein R3 is methyl-phenyl or chloro- phenyl.
[0134] Clause 21. The method of any of clauses 12-20, wherein R4 is methoxy-phenyl or phenyl substituted with pyridyl.
[0135] Clause 22. The method of any of clauses 12-21, wherein the compound is selected from the group consisting of 4-(T-isopropyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-lH,rH-[3,4'- bipyrazol]-2(5H)-yl)-4-oxobutanoic acid, 3-(3'-(4-chlorophenyl)-5-(4-methoxyphenyl)-T- phenyl-3,4-dihydro-l'H,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, 3-(l',5-bis(4- methoxyphenyl)-3'-(p-tolyl)-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, and 3-(3'-(4-methylphenyl)-5-(4-methoxyphenyl)-r-phenyl-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2- tetrazole.
[0136] Clause 23. A method to modulate a protein-protein interaction between pore and auxiliary subunits of a voltage-gated ion channel in a nerve cell, comprising contacting the nerve cell with an effective amount of the compound of Formula (la)
[0137] wherein
[0138] Rla is C(0)R1 or phenyl optionally substituted with one or more -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl, wherein R1 is -C1-C4 alkyl-CCkH, -C1-C4 alkyl-C(0)Ci-C4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl;
[0139] R2 is phenyl, heteroaryl, -C1-C4 alkyl-phenyl, or -C1-C4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy;
[0140] R3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C3 alkyl, halo, -C1-C4 alkoxy, or heteroaryl; and
[0141] R4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy, piperazinyl, or heteroaryl;
[0142] or a pharmaceutically acceptable salt thereof.
[0143] Clause 24. A method to modulate a protein-protein interaction between pore and auxiliary subunits of a voltage-gated ion channel in a nerve cell, comprising contacting the nerve cell with an effective amount of the compound of Formula (1)
[0144] wherein
[0145] R1 is selected from the group consisting of -(C1-C4 alkyl)-C02H, and -CO2H and tetrazole substituted phenyl;
[0146] R2 is selected from the group consisting of phenyl, methoxy substituted phenyl, and pyridinyl;
[0147] R3 is selected from the group consisting of (C1-C3 alkyl) substituted phenyl and halo substituted phenyl; and
[0148] R4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridyl.
[0149] Clause 25. The method of clause 23 or clause 24, wherein the pore forming subunit is CaVal.
[0150] Clause 26. The method of any of clauses 23-25, wherein the the auxiliary subunit is CaV or a pharmaceutically acceptable salt thereof.
[0151] Clause 27. The method of any of clauses 23-26, wherein the neurological disorder is pain.
[0152] Clause 28. The method of any of clauses 23-27, wherein R1 is selected from the group consisting of CO2H substituted phenyl, tetrazole substituted phenyl, and -(CFF^CCkFl.
[0153] Clause 29. The method of any of clauses 23-28, wherein R1 is -(CFF^CCkFl.
[0154] Clause 30. The method of any of clauses 23-29, wherein R2 is phenyl, methoxy substituted phenyl, or heteroaryl.
[0155] Clause 31. The method of any of clauses 23-30, wherein R2 is phenyl.
[0156] Clause 32. The method of any of clauses 23-31, wherein R2 is methoxy substituted phenyl.
[0157] Clause 33. The method of any of clauses 23-32, wherein R3 is methyl-phenyl or chloro- phenyl.
[0158] Clause 34. The method of any of clauses 23-33, wherein R4 is methoxy-phenyl or phenyl substituted with pyridyl.
[0159] Clause 35. The method of any of clauses 23-34, wherein the compound is selected from the group consisting of 4-(T-isopropyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-lH,rH-[3,4'- bipyrazol]-2(5H)-yl)-4-oxobutanoic acid, 3-(3'-(4-chlorophenyl)-5-(4-methoxyphenyl)-l'- phenyl-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, 3-(l',5-bis(4- methoxyphenyl)-3'-(p-tolyl)-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, and 3-(3'-(4-methylphenyl)-5-(4-methoxyphenyl)-r-phenyl-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2- tetrazole.
[0160] Clause 36. A compound selected from the group consisting of
pharmaceutically acceptable salt thereof.
[0161] Clause 37. The compound of clause 36, selected from the group consisting of
pharmaceutically acceptable salt thereof.
[0162] Clause 38. Use of a compound according to any one of clauses 1-10, 36, or 37, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating a neurological disorder in a patient.
[0163] Clause 39. The use of clause 38, wherein the neurological disorder is pain.
[0164] Clause 40. A compound according to any one of clauses 1-10, 36, or 37, or a pharmaceutically acceptable salt thereof, for treating a neurological disorder in a patient.
CHEMICAL SYNTHESIS
[0165] Exemplary chemical entities useful in methods of the description will now be described by reference to illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Furthermore, one of skill in the art will recognize that the transformations shown in the schemes below may be performed in any order that is compatible with the functionality of the particular pendant groups.
[0166] Abbreviations: The examples described herein use materials, including but not limited to, those described by the following abbreviations known to those skilled in the art:
General Method 1
[0167] The compounds of the present invention, or salts thereof, may be prepared by a variety of procedures known to one of ordinary skill in the art, some of which are illustrated in the schemes, preparations, and examples below. One of ordinary skill in the art recognizes that the specific synthetic steps for each of the routes described may be combined in different ways, or
in conjunction with steps from different schemes, to prepare compounds of the invention, or salts thereof. The products of each step in the schemes below can be recovered by conventional methods well known in the art, including extraction, evaporation, precipitation, chromatography, filtration, trituration, and crystallization. In the schemes below, all substituents unless otherwise indicated, are as previously defined. The reagents and starting materials are readily available to one of ordinary skill in the art. Others may be made by standard techniques of organic and heterocyclic chemistry which are analogous to the syntheses of known structurally- similar compounds and the procedures described herein which follow including any novel procedures. Without limiting the scope of the invention, the following schemes, preparations, and examples are provided to further illustrate the invention. In addition, one of ordinary skill in the art appreciates that the compounds of Formula 1 may be prepared by using starting material with the corresponding stereochemical configuration which can be prepared by one of skill in the art.
[0168] Scheme 1
[0169] A compound of Formula 1 can be prepared in accordance with reactions as depicted in Scheme 1. With reference to compounds of Formula (1) or Formula (la), intermediate compound la can be synthesized from phenylhydrazine and 4’-methylacetophenone by simple condensation (step a). Intermediate la can be stored in darkness, under argon gas at 4°C. Excess Vilsmeier reagent (DMF+POCF) can be added to intermediate la to generate intermediate lb (step b). Condensation with substituted acetophenones yields the intermediate enone lc (step c). Subsequent coupling with excess hydrazine hydride yields the second 4,5-
dihydropyrazole ring in intermediate compound ld (step d). An amidation can be carried out using anhydrous pyridine to generate intermediate le (step e). Hydrolysis using 2 M LiOH aqueous solution in methanol/THF co-solvents at r.t. results in compound 1 (step f).
[0170] The following preparations and examples further illustrate the invention and represent typical synthesis of the compounds of Formula (1).
** indicates that the amide bond is missing from this compound.
[0171] Example l-la
[0172] 1 -phenyl-2-( 1 -phenylethylidene) -hydrazine
[0173] A mixture of l-(p-tolyl)ethanone (2.68 g, 20 mmol), phenylhydrazine (2.16 g, 20 mmol) and acetic acid (260 mg, 2 mmol) in anhydrous ethanol (25 mL) was refluxed under N2 for 12 h. After removal of ethanol, the residue was dissolved in ethyl acetate (100 mL). The organic phase was washed with water (100 mL), dried over Na2S04 and concentrated under reduced pressure. The residue was purified by column chromatography with PE/EA (8:1) to give the desired product as a light yellow solid (3.6 g, 86% yield). 1 H NMR (400 MHz, CDCI3) d 7.69 (d, J = 8.0 Hz, 2H), 7.30-7.26 (m, 2H), 7.18 (m, 4H), 6.87 (t, J = 7.2 Hz, 1H), 2.37 (s, 3H), 2.23 (s, 3H). ESIMS (m/z) for CI5HI7N2 + [M+H]+ : calculated 225.11, found 225.10.
[0174] Example 2- lb
[0175] l-phenyl-5-(p-tolyl)-lH-pyrazole-3-carbaldehyde
[0176] A solution of l-phenyl-2-(l-phenylethylidene)hydrazine (1.8 g, 8.6 mmol) in the Vilsmeier reagent (20 mL) was stirred at 65°C overnight. The mixture was cooled to room temperature, and poured into an ice-water (50 mL). The product (2 g, 89% yield) was obtained upon neutralization with NaHCCb and filtration. 1 H NMR (400 MHz, CDCb): d 10.05 (s, 1H), 8.53 (s, 1H), 7.80-7.78 (d, J = 8.0 Hz, 2H), 7.73-7.71 (d, J = 8.0 Hz, 2H), 7.53-7.49 (m, 2H), 7.39 (m, 1H), 7.32-7.31 (d, J = 7.6 Hz, 2H), 2.43(s, 3H). ESIMS (m/z) for CI7HI5N20 + [M+H]+ : calculated 263.11, found 263.10.
[0177] Example 3-lc
[0178] l-(4-methoxyphenyl)-3-(l-phenyl-5-(p-tolyl)-lH-pyrazol-3-yl)prop-2-en-l-one
[0179] A mixture of l-phenyl-5-(p-tolyl)-lH-pyrazole-3-carbaldehyde (284 mg, 2.0 mmol) and l-(4-methoxyphenyl)-ethanone (500 mg, 2.0 mmol) in EtOH (20 mL) was added to a stirred solution of 10% KOH. The reaction mixture was stirred at 25 °C for 3 h. The precipitate was filtered and the solid was washed with EtOH. The solid was collected and dried to give the desired product as a light yellow solid (680 mg, 91% yield). 1 H NMR (400 MHz, CDCI3): d 8.33 (s, 1H), 7.98-7.96 (d, J = 8.8 Hz, 2H), 7.90-7.86 (d, J = 15.6 Hz, 1H), 7.81-7.79 (d, J = 8.4 Hz, 2H), 7.62-7.60 (d, J = 8.0 Hz, 2H), 7.53-7.47 (t, J = 8.0 Hz, 2H), 7.39-7.26 (m, 4H), 6.97- 6.95 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H), 2.43 (s, 3H). ESIMS (m/z) for C26H23N202 + [M+H]+ : calculated 395.17, found 395.21.
[0180] Example 4-ld
[0181] 5'-(4-methoxyphenyl)-l-phenyl-5-(p-tolyl)-3',4'-dihydro-lH,2'H-3,3'-bipyrazole
[0182] To a solution of l-(4-methoxyphenyl)-3-(l-phenyl-5-(p-tolyl)-lH-pyrazol-3-yl)-prop-2- en-l-one (400 mg, 1.0 mmol) and hydrazine hydrate (75 mg, 1.5 mmol) in EtOH ( 20 mL), a few drops of piperidine were added. The reaction of mixture was refluxed for 2.5 h. The suspension was cooled to room temperature, and a white precipitate was filtered and washed with EtOH. The solid was collected and dried to afford the desired product as a white solid (390 mg, 93% yield). 1H NMR (400 MHz, CDCl3): d 8.02 (s, 1H), 7.73-7.71 (d, J = 8.0 Hz, 2H), 7.63-7.60 (m, 4H), 745-7.41 (m, 2H),7.28 (m, 3H), 6.92-6.90 (d, J = 8.8 Hz, 2H), 5.88 (br, 1H), 5.14-5.10 (m, 1H), 3.82 (s, 3H), 3.48-3.42 (m, 1H), 3.08-3.02 (m, 1H), 2.43 (s, 3H). ESIMS (m/z) for C26H25N4O + [M+H]+ : calculated 409.20, found 409.20.
[0183] Example 5-le
[0184] 4-(5'-(4-methoxyphenyl)-l-phenyl-5-(p-tolyl)-3',4'-dihydro-lH,2'H-[3,3'-bipyrazol]-2'- yl)-4-oxobutanoate
[0185] Methyl 4-chloro-4-oxobutanoate (0.24 mmol) was added dropwise to a solution of 5'-(4- methoxyphenyl)-l-phenyl-5-(p-tolyl)-3',4'-dihydro-lH,2'H-3,3'-bipyrazole ((100 mg, 0.24 mmol) in pyridine (3 mL). The mixture was stirred at room temperature overnight. The mixture was evaporated to remove the solvent under reduced pressure, and the residue was dissolved in EA (30 mL). The mixture was washed with water (20 mL x2) and brine (20 mL). The organic phase was dried over Na2S04, filtered, and concentrated. The residue was purified by column chromatography (PE/EA= 3: 1) to give the desired product as a white solid (51 mg, 41% yield). ¾ NMR (400 MHz, CDCI3): d 7.91 (s, 1H), 7.77-7.75 (d, J = 7.6 Hz, 2H), 7.65- 7.59 (m, 4H), 7.41-7.37 (m, 2H), 7.26-7.20 (m, 3H), 6.90-6.88 (d, J = 8.8 Hz, 2H), 5.93-5.89 (dd, J = 11.2,4.0 Hz, 1H), 3.83 (s, 3H), 3.69 (s, 3H), 3.62-3.55 (dd, J = 17.2,11.2 Hz, 1H), 3.60- 3.53 (m, 1H), 3.08-3.02 (m, 1H), 2.96-2.85 (m,lH), 2.72 (m, 1H), 2.38 (s, 3H). ESIMS (m/z) for C31H31N4CV [M+H]+ : calculated 523.23, found 523.20.
[0186] Example 6-1
[0187] 4-(5'-(4-methoxyphenyl)-l-phenyl-5-(p-tolyl)-3',4'-dihydro-lH,2'H-[3,3'-bipyrazol]-2'- yl)-4-oxobutanoic acid
[0188] Methyl 4-(5'-(4-methoxyphenyl)-l-phenyl-5-(p-tolyl)-3',4'-dihydro-lH,2'H-[3,3'- bipyrazol]-2'-yl)-4-oxobutanoate ( 51 mg, 0.1 mmol) was added to a suspension of LiOH.H20 (
42 mg, 1.0 mmol) in mixture of THF/MeOH/H20 (5 mL, v/v/v =3:1:1). The mixture was stirred at 25°C overnight. The mixture was cooled with an ice-bath, and adjusted to pH=4-5
with 1 N HC1 The mixture was extracted with EA (15 mLx3). The combine organic layers were washed with water, brine, and dried with Na2S04. The solution was filtered and concentrated under reduced pressure. The residue was purified by prep. HPLC to afford the desired product as white solid (30.1 mg, 59% yield). 1 H NMR (400 MHz, CDCb): d 7.80 (s, 1H), 7.70-7.68 (d, J = 7.6 Hz, 2H), 7.60-7.58 (M, 4H), 7.41-7.37 (m, 2H), 7.26-7.22 (m, 3H), 6.90-6.88 (d, J = 8.8 Hz, 2H), 5.90-5.86 (dd, J = 11.2,4.0 Hz, 1H), 3.84 (s, 3H), 3.63-3.56 (dd, J = 17.2,11.2 Hz, 1H), 3.27-3.24 (m, 1H), 3.08-3.00 (m, 2H), 2.81-2.73 (m, 2H), 2.37(s, 3H); 13C NMR (100 MHz, CDCb): d 161.60, 150.16, 139.88, 137.91, 130.24, 129.32, 129.26, 128.40, 128.15, 126.30, 125.80, 123.66, 121.92, 119.02, 114.12,55.40, 52.69, 42.09, 29.04, 21.26. ESIMS (m/z) for C3oH29N404 + [M+H]+ : calculated 509.21, found 509.20.
[0189] Scheme 2
[0190] Scheme 2 depicts a route for synthesizing compound 3. fir
3d 3e
[0191] Example 7-3a
[0192] l-(4-bromophenyl)-3-(l-phenyl-3-(p-tolyl)-lH-pyrazol-4-yl)prop-2-en-l-one
[0193] This compound was prepared essentially by the method of Example 3 (1.06 g, 76 % yield). ¾ NMR (400 MHz, CDCb): d 8.34 (s, 1H), 7.92-7.88 (d, J = 15.6 Hz, 1H), 7.83-7.78 (m, 4H), 7.63-7.58 (m, 4H), 7.52-7.48 (t, J = 8.0 Hz, 2H), 7.37-7.26 (m, 4H), 2.43 (s, 3H). ESIMS (m/z) for C25H2oBrN20 + [M+H]+ : calculated 443.07, found 443.10.
[0194] Example 8-3b
[0195] 5-(4-bromophenyl)-l'-phenyl-3'-(p-tolyl)-3, 4-dihydro- l'H,2H-3,4'-bipyrazole
[0196] This compound was prepared essentially by the method of Example 4 (0.49 g, 95% yield). ¾ NMR (400 MHz, CDCb): d 8.00 (s, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.60-7.58 (d, J = 8.4 Hz, 2H), 7.45-7.41 (t, J = 8.0 Hz, 2H), 7.28-7.26 (m, 3H), 6.01 (br, 1H), 5.18-5.13 (m,lH), 3.47-3.40 (m, 1H), 3.06-3.00 (m, 1H), 2.41 (s, 3H). ESIMS (m/z) for C25H22BrN4 + [M+H]+ : calculated 457.09, found 457.10.
[0197] Example 9-3c
[0198] Methyl 4-(5-(4-bromophenyl)-l'-phenyl-3'-(p-tolyl)-3, 4-dihydro- TH,2H-[3, 4'- bipyrazol]-2-yl)-4-oxobutanoate
[0199] This compound was prepared essentially by the method of Example 5 (0.49 g, 95% yield). ¾ NMR (400 MHz, CDCb): d 7.93 (s, 1H), 7.76 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 8.0 Hz, 2H), 7.60 (m, 4H), 7.41-7.37 (t, J = 7.6 Hz, 2H), 7.26-7.21 (m, 4H), 5.92-5.88 (m,lH), 3.69 (s, 3H), 3.63-3.55 (m, 1H), 3.35 (m, 1H), 3.08-3.02 (m, 1H), 2.93-2.85 (m, 2H), 2.72-2.71 (m, 1H), 2.37 (s, 3H). ESIMS (m/z) for CstTHsBr^C + [M+H]+ : calculated 571.13, found 571.10.
[0200] Example l0-3d
[0201] tert-butyl 4-(4-(2-(4-methoxy-4-oxobutanoyl)-l'-phenyl-3'-(p-tolyl)-3,4-dihydro-
1 Ή,2H- [3 ,4'- bipyrazol] -5 -yl)phenyl)piperazine- 1 -carboxylate
[0202] A mixture of intermediate compound 3c (0.1 g, 0.18 mmol), tertbutyl piperazine- 1- carboxylate (60 mg, 0.35 mmol), Pd2(dba)3 (32 mg, 0.04 mmol), xPhos (25 mg, 0.05 mmol), and CS2C03 (114 mg, 0.35 mmol) in anhydrous dioxane (15 mL) under N2 was refluxed overnight. The solvent was removed. EtOAc (20 mL) was added. The mixture was washed with water and brine. The organic phase was dried with Na2S04, filtered, and concentrated. The residue was purified by prep.-TLC (PE/AE=2:l) to give the desired product (0.75 g, 49% yield). ¾ NMR (400 MHz, CDCb): d 7.90 (s, 1H), 7.76 (d, J = 8.0 Hz, 2H), 7.65 (d, J = 7.6 Hz, 2H), 7.56 (d, J = 8.0 Hz, 2H), 7.38 (t, J = 7.6 Hz, 2H), 7.26-7.21 (m, 4H), 6.85 (d, J = 8.4 Hz, 2H), 5.92-5.88 (m, 1H), 3.68 (s, 3H), 3.60-3.54 (m, 5H), 3.40-3.36 (m, 1H), 3.21 (s, 4H), 3.06-3.01 (m, 1H), 2.95-2.85 (m, 2H), 2.72-2.70 (m, 1H), 2.39 (s, 3H), 1.48 (s, 9H). ESIMS (m/z) for C39H45N6O5 + [M+H]+ : calculated 677.34, found 677.30.
[0203] Example l l-3e
[0204] 4-(5-(4-(4-(tert-butoxycarbonyl)piperazin-l-yl)phenyl)-T-phenyl-3'-(p-tolyl)-3,4- dihydro-l'H,2H-[3,4'-bipyrazol]-2-yl)-4-oxobutanoic acid
[0205] This compound was prepared essentially by the method of Example 6 (145 mg, 81% yield). lH NMR (400 MHz, CDCl3): d 7.79 (s, 1H), 7.70-7.68 (d, J = 8.0 Hz, 2H), 7.64-7.62 (d, J = 8.0 Hz, 2H), 7.57-7.55 (d, J = 8.8 Hz, 2H), 7.42-7.38 (t, J = 8.0 Hz, 2H), 7.26-7.23 (m, 4H), 6.87-6.85 (d, J = 8.8 Hz, 2H), 5.92-5.88 (dd, J = 11.2,3.6 Hz, 1H), 3.63-3.57 (m, 5H), 3.29-2.24 (m, 5H), 3.11-3.06 (m, 2H), 2.81-2.75 (m, 2H), 2.38 (s, 3H). ESIMS (m/z) for C38H43N6O5 + [M+H]+ : calculated 663.32, found 663.30.
[0206] Example 12-3
[0207] 4-oxo-4-(T-phenyl-5-(4-(piperazin-l-yl)phenyl)-3'-(p-tolyl)-3,4-dihydro-rH,2H-[3,4'- bipyrazol]-2-yl)butanoic acid
[0208] 4-oxo-4-(T-phenyl-5-(4-(piperazin-l-yl)phenyl)-3'-(p-tolyl)-3,4-dihydro-rH,2H-[3,4'- bipyrazol]-2-yl)butanoic acid
[0209] A solution of intermediate 3e (138 mg, 0.21 mmol) in DCM (0.5 mL) was added to a solution of HC1/DCM (10 mL), and the reaction mixture was stirred at room temperature for 1 h. The solvent was removed. The residue was purified by prep. HPLC to give the desired product as white solid (10 mg, 9% yield). 1 H NMR (400 MHz, DMSO-d6): d 8.18 (m, 2H), 7.85 (m, 2H), 7.68 (m, 2H), 7.60 (m, 2H), 7.47 (m, 2H), 7.29 (m, 2H), 6.97 (m, 2H), 5.68 (m, 1H), 3.89-3.77 (m, 10H), 2.95 (m, 4H), 2.37 (s, 3H). ESIMS (m/z) for C33H35N6O3 + [M+H]+ : calculated 563.27, found 563.30.
[0210] Scheme 3
[0211] Scheme 3 depicts a route for synthesizing compound 4.
[0212] Example l3-4a
[0213] l-(4-(pyridin-2-yl)phenyl)ethanone
[0214] A mixture of (4-acetylphenyl)boronic acid (500 mg, 3.7 mmol), 2-bromopyridine (560 mg, 3.1 mmol), Pd(PPh3)4 (350 mg, 0.31 mmol), and K2CO3 (860 mg, 6.2 mml) in a mixture of dioxane and water (v/v=5:l, 50 mL) under N2 was refluxed for 4 h. The mixture was evaporated to remove the solvent under reduced pressure. The residue was mixed with EtOAc (50 mL), and the mixture was washed with water and brine. The organic phase was dried with Na2S04, filtered, and concentrated. The residue was purified by column chromatography (PE/EA=5:l) to give the desired product (550 mg, 90% yield). 1 H NMR (400 MHz, DMSO- d6): d 8.74 (d, 7 = 4.8 Hz, 1H), 8.12-8.05 (m, 4H), 7.8(d, 7 = 3.6 Hz, 2H), 7.3-7.26 (m, 1H), 2.65 (s, 3H). ESIMS (m/z) for C13H12NO + [M+H]+ : calculated 198.08, found 198.10.
[0215] Example l4-4b
[0216] 3-(l-phenyl-3-(p-tolyl)-lH-pyrazol-4-yl)-l-(4-(pyridin-2-yl)phenyl)prop-2-en-l-one
[0217] This compound was prepared essentially by the method of Example 3 (300 mg, 74 % yield). ¾ NMR (400 MHz, CDCb): d 8.75 (d, 7 =5.2 Hz, 1H), 8.37 (s, 1H), 8.14-8.12 (d, 7 = 8.0 Hz, 2H), 8.09-8.06 (d, 7 = 7.6 Hz, 2H), 7.95-7.91 (d, 7 = 15.6 Hz, 1H), 7.82 (m, 4H), 7.62 (d, 7 = 7.6 Hz, 2H), 7.52-7.48 (m, 2H), 7.40-7.36 (m, 1H), 7.35- 7.32 (d, 7 = 8.4 Hz, 1H), 7.30
(m, 3H), 2.43 (s, 3H). ESIMS (m/z) for C30H24N3O + [M+H]+ : calculated 442.18, found 442.20.
[0218] Example l5-4c
[0219] 5-(4-(pyridin-2-yl)phenyl)-3'-(p-tolyl)-3,4-dihydro-rH,2H-3,4'-bipyrazole
[0220] This compound was prepared essentially by the method of Example 4 (242 mg, 78% yield). lH NMR (400 MHz, CDCI3): d 8.70 (s, 1H), 8.04 (m, 3H), 7.08-7.72 (m, 7H), 7.62 (m, 2H), 7.42 (m, 3H), 6.03 (m, 1H), 5.19 (m, 1H), 3.56-3.50 (m, 1H), 3.16-3.10 (m, 1H), 2.41 (s, 3H). ESIMS (m/z) for C3oH26N5 + [M+H]+ : calculated 456.21, found 456.20.
[0221] Example l6-4d
[0222] Methyl-4-oxo-4-(r-phenyl-5-(4-(pyridin-2-yl)phenyl)-3'-(p-tolyl)-lH,rH[3,4'- bipyrazol]-2(5H)-yl)butanoate
[0223] This compound was prepared essentially by the method of Example 5 (182 mg, 60% yield). lH NMR (400 MHz, DMSO-d6): d 8.72 (d, J = 4.8 Hz, 1H), 8.04-8.02 (d, J = 8.4 Hz, 2H), 7.95 (s, 1H), 7.78-7.75 (m, 6H), 7.65-7.63 (d, J = 8.0 Hz, 2H), 7.39 (m, 2H), 7.23 (m, 6H), 5.98-5.94 (dd, J = 11.2,4.0 Hz, 1H), 3.70 (s, 3H), 3.67 (m, 1H), 3.46-3.38 (m, 1H), 3.16-3.15 (m, 2H), 3.12-3.00 (m, 1H), 2.74 (m, 1H), 2.38 (s, 3H). ESIMS (m/z) for Css^NsCb* [M+H]+ : calculated 570.24, found 570.20.
[0224] Example 17-4
[0225] 4-oxo-4-(l'-phenyl-5-(4-(pyridin-2-yl)phenyl)-3'-(p-tolyl)-lH,rH-[3,4'-bipyrazol]- 2(5H)-yl)butanoic acid
[0226] This compound was prepared essentially by the method of Example 6 (59 mg, 41% yield). lH NMR (400 MHz, DMSO-d6): d 8.69 (d, J = 4.0 Hz, 1H), 8.30 (s, 1H), 8.18 (d, J = 8.4 Hz, 2H), 8.02 (d, J = 8.4 Hz, 2H), 7.92-7.82 (m, 5H), 7.69 (d, J = 8.0 Hz, 2H), 7.49-7.45 (m, 2H), 7.40-7.37 (m,lH), 7.31-7.26 (m, 2H), 5.76-5.72 (dd, J = 11.6, 4.8 Hz, 1H), 3.93 (m,lH), 3.26-3.21 (m, 1H), 2.93 (m, 1H) 2.57-2.54 (m, 1H), 2.36 (s, 3H); 13C NMR (100 MHz, DMSO-d6): 174.51, 169.63, 155.54, 154.14, 150.14, 149.72, 140.49, 139.87, 137.82, 132.23, 129.92, 129.67, 128.28, 127.54, 127.16, 126.86, 126.60, 123.55, 120.94, 118.62, 52.77, 42.40, 29.34, 29.07, 21.33. ESIMS (m/z) for C34H30N5O3 + [M+H]+ : calculated 556.23, found 556.20.
[0227] Example l8-5a
[0228] l-isopropyl-2-(l-(p-tolyl)ethylidene)hydrazine
[0229] This compound was prepared essentially by the method of Example 1 (0.9 g, 65 % yield). ESIMS (m/z) for C12H19N2 + [M+H]+ : calculated 191.15, found 191.10.
[0230] Example 19- 5b
[0231] l-isopropyl-3-(p-tolyl)- lH-pyrazole-4-carbaldehyde
[0232] This compound was prepared essentially by the method of Example 2 (460 mg, 37% yield). lH NMR (400 MHz, CDCI3): d 9.93 (s, 1H), 8.06 (s, 1H), 7.61 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 4.56 (M, 1H), 2.40 (s, 3H), 1.58 (d, J = 6.8 Hz, 6H). ESIMS (m/z) for C14H17N2O + [M+H]+ : calculated 229.13, found 229.10.
[0233] Example 20-5c
[0234] 3-(l-isopropyl-3-(p-tolyl)-lH-pyrazol-4-yl)-l-(4-methoxyphenyl)prop-2-en-l-one
[0235] This compound was prepared essentially by the method of Example 3 (569 mg, 90% yield). ¾ NMR (400 MHz, CDCb): d 7.96 (d, J = 8.8 Hz, 2H), 7.85 (d, J = 8.0 Hz, 2H), 7.52 (d, J = 8.0 Hz, 2H), 6.96 (d, J = 8.8 Hz, 2H), 4.56 (M, 1H), 3.87 (s, 3H), 2.40 (s, 3H), 1.59 (d, J = 6.4 Hz, 6H). ESIMS (m/z) for C23H25N202 + [M+H]+ : calculated 361.18, found 361.20.
[0236] Example 2l-5d
[0237] T-isopropyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-3, 4-dihydro- TH,2H-3,4'-bipyrazole
[0238] This compound was prepared essentially by the method of Example 4 (255 mg, 74% yield). lH NMR (400 MHz, CDCb): d 7.62 (d, J = 8.4 Hz, 2H), 7.49 (m, 3H), 7.24 (d, J = 8.0 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 5.06-5.02 (m, 1H), 4.50-4.47 (m, 1H), 3.83 (s, 3H), 3.71 (m,lH), 3.42-3.35 (m, 1H), 3.02- 2.96 (m, 1H), 2.38 (s, 3H), 1.52 (d, J = 6.4 Hz, 6H). ESIMS (m/z) for C23H27N4O +[M+H]+ : calculated 375.21, found 375.20.
[0239] Example 22-5e
[0240] 4-(r-isopropyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-lH,TH-[3,4'-bipyrazol]-2(5H)-yl)-4- oxobutanoate
[0241] This compound was prepared essentially by the method of Example 5 (120 mg, 36% yield). lH NMR (400 MHz, CDCI3): d 7.58 (d, J = 8.8 Hz, 1H), 7.20 (d, J = 8.0 Hz, 2H), 7.32 (s, 1H), 7.17 (d, J = 8.0 Hz, 2H), 6. 88 (d, J = 8.8 Hz, 2H), 5.84-5.80 (dd, J = 11.6, 4.0 Hz, 1H), 4.44-4.41 (m, 1H), 3.84 (s,3H), 3.69 (s, 3H), 3.55-3.48 (m, 1H), 3.28-3.22 (m, 1H), 3.01- 2.95 (m, 2H), 2.81-2.67 (m, 2H), 2.34 (s, 3H), 1.48 (d, J = 6.4 Hz, 6H). ESIMS (m/z) for C28H33N4O4 + [M+H]+ : calculated 489.24, found 489.20.
[0242] Example 23-5
[0243] 4-(r-isopropyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-lH,rH-[3,4'-bipyrazol]-2(5H)-yl)-4- oxobutanoic acid
[0244] This compound was prepared essentially by the method of Example 6 (87 mg, 77% yield). ¾ NMR (400 MHz, CDCb): d 7.58 (d, J = 8.8 Hz, 1H), 7.51-7.49 (d, J = 8.0 Hz, 2H), 7.27 (s, 1H), 7.l7(d, J = 8.0 Hz, 2H), 6.91-6.88 (d, J = 8.8 Hz, 2H), 5.83-5.79 (dd, J = 11.2,4.0 Hz, 1H), 4.45-4.41 (m, lH),3.84 (s,3H), 3.58-3.51 (dd, J = 17.2, 11.2 Hz, 1H), 3.23-3.20 (m, 1H), 3.10-3.00 (m, 2H), 2.80-2.73 (m, 2H), 2.34 (s, 3H),l.48 (d, J = 6.8 Hz, 6H); 13C NMR (100 MHz,CDCl3): <5 161.60, 150.16, 139.88, 137.91, 130.24, 129.32, 129.26, 128.40, 128.15, 126.30, 125.80, 123.66, 121.92, 119.02, 114.12,55.40, 52.69, 42.09, 29.04, 21.26. ESIMS (m/z) for C27H31N4CV [M+H]+ : calculated 475.23, found 475.20.
[0245] Example 24-6e (7)
[0246] Methyl 3-(5-(4-methoxyphenyl)-T-phenyl-3'-(p-tolyl)-2, 5-dihydro- 1H,1Ή-[3, 4'- bipyrazole]-2-carbonyl)benzoate
[0247] This compound was prepared essentially by the method of Example 5. 1 H NMR (400 MHz, CDCb): d 8.80 (s, 1H), 8.19 (m, 2H), 7.87 (s, 1H), 7.68 (d, J = 7.2 Hz, 4H), 7.59-7.52 (m, 3H), 7.39 (t, J = 7.6 Hz, 2H), 7.24 (m, 2H), 6.89 (d, J = 8.8 Hz, 2H), 6.09 (m, 1H), 3.96 (s, 3H), 3.83 (s, 3H), 3.68-3.61 (dd, J = 17.611.6 Hz, 1H), 3.17-3.12 (dd, 7 = 17.23.6 Hz, 1H), 2.38 (s, 3H). ESIMS (m/z) for C35H31N4OT [M+H]+ : calculated 571.23, found 571.20.
[0248] Example 25-6
[0249] 3-(5-(4-methoxyphenyl)-T-phenyl-3'-(p-tolyl)-2,5-dihydro-lH,rH-[3,4'-bipyrazole]-2- carbonyl)benzoic acid
[0250] This compound was prepared essentially by the method of Example 6. 1 H NMR (400 MHz, CDCI3): d 8.88 (s, 1H), 8.25 (s, 2H), 7.88 (s, 1H), 7.69 (d, J = 7.6 Hz, 4H), 7.58 (m, 3H), 7.39 (m, 2H), 7.24 (m, 2H), 6.89 (d, J = 8.4 Hz, 2H), 6.11 (m, 1H), 3.82 (m, 1H), 3.17 (m,lH), 2.38 (s, 3H); 13C NMR (100 MHz, CDCb): 161.58, 155.52, 150.65, 139.89, 137.97, 134.94, 132.44, 132.17, 129.33, 129.27, 128.46, 128.36, 128.04, 126.38, 125.73, 123.73, 122.19, 119.13, 114.16, 55.37, 53.66, 41.44, 21.27. ESIMS (m/z) for C34H29N4O4 + [M+H]+ : calculated 557.21, found 557.20.
[0251] Example 26-8a
[0252] l-(l-(4-chlorophenyl)ethylidene)-2-phenylhydrazine
[0253] This compound was prepared essentially by the method of Example 1 (yellow solid, 1.7 g, 90% yield). lH NMR (400 MHz, CDCl3): d 7.72-7.70 (d, J = 8.8 Hz, 2H), 7.69-7.25 (m, 5H), 7.17 (d, J = 7.6 Hz, 2H), 6.90-6.87 (t, J = 7.2 Hz, 1H), 2.38 (s, 3H). ESIMS (m/z) for C14H14CIN2 + [M+H]+ : calculated 225.08, found 225.10.
[0254] Example 27-8b
[0255] 3 -(4-chlorophenyl)- 1 -phenyl- lH-pyrazole-4-carbaldehyde
[0256] This compound was prepared essentially by the method of Example 2 (light yellow solid, l.44g, 68% yield). ¾ NMR (400 MHz, CDCb): d 10.04 (s, 1H), 8.53 (s, 1H), 7.84-7.82 (d, J = 8.4 Hz, 2H), 7.80-7.78 (d, J = 8.4 Hz, 2H), 7.53-7.48 (m, 4H), 7.46-7.41 (t, J = 7.6 Hz, 1H). ESIMS (m/z) for Ci6Hi2ClN20 + [M+H]+ : calculated 283.06, found 283.10.
[0257] Example 28-8c
[0258] 3-(3-(4-chlorophenyl)-l-phenyl-lH-pyrazol-4-yl)-l-(4-methoxyphenyl)prop-2-en-l-one
[0259] This compound was prepared essentially by the method of Example 3 (light yellow solid, 1.76 g, 83% yield). lH NMR (400 MHz, CDCb): d 8.34 (s, 1H), 7.99-7.97 (d, J = 8.8 Hz, 2H), 7.86-7.82 (d, J = 15.6 Hz, 1H), 7.80-7.78 (d, J = 7.6 Hz, 2H), 7.68-7.66 (d, J = 8.4 Hz, 1H), 7.52-7.46 (m, 4H), 7.40-7.35 (m, 2H), 6.99-6.96 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H). ESIMS (m/z) for C25H2oClN202 + [M+H]+ : calculated 415.11, found 415.10.
[0260] Example 29- 8d
[0261] 3'-(4-chlorophenyl)-5-(4-methoxyphenyl)-r-phenyl-3,4-dihydro-TH,2H-3,4'-bipyrazole
[0262] This compound was prepared essentially by the method of Example 4 (white solid, 672 mg, 86% yield). ¾ NMR (400 MHz, CDCI3): d 8.03 (s, 1H), 7.72 -7.67 (m, 3H), 7.63-7.61 (m, 1H), 7.46-7.42 (m, 4H), 7.31 -7.27 (m, 1H), 6.93-6.91 (d, J = 8.8 Hz, 2H), 5.13 (m, 1H), 3.68- 3.62 (m,lH), 3.17-3.12 (m,lH). ESIMS (m/z) for C25H22ClN40 + [M+H]+ : calculated 429.14, found 429.10.
[0263] Example 30-8e
[0264] Methyl 3-(3'-(4-chlorophenyl)-5-(4-methoxyphenyl)-r-phenyl-3,4-dihydro-TH, 2H- [3 ,4'-bipyrazole] -2-carbonyl)benzoate
[0265] This compound was prepared essentially by the method of Example 5 (white solid, 340 mg, 62% yield). ¾ NMR (400 MHz, CDCb): d 8.80 (s, 1H), 8.21-8.27 (m, 2H), 7.89 (s, 1H),
7.78-7.76 (d, J = 8.0 Hz, 2H), 7.68-7.66(d, J = 7.6 Hz, 2H), 7.60-7.58 (m, 2H), 7.56-7.52 (m,
1H), 7.42-7.39 (m, 4H), 7.26 (m, 1H), 6.92-6.90 (d, J = 8.8 Hz, 2H), 6.07-6.03 (m, 1H), 3.96 (s,
3H), 3.84 (s, 3H), 3.71-3.64 (m,lH), 3.16-3.11 (m, 1H). ESIMS (m/z) for C34H28ClN404 + [M+H]+ : calculated 591.17, found 591.20.
[0266] Example 31-8
[0267] 3-(3'-(4-chlorophenyl)-5-(4-methoxyphenyl)-r-phenyl-3,4-dihydro-rH,2H-[3,4'- bipyrazole]-2-carbonyl)benzoic acid
[0268] This compound was prepared essentially by the method of Example 6 (white solid, 50 mg, 87% yield). lH NMR (400 MHz, CDCh): d 8.85 (s, 1H), 8.24-8.23 (d, J = 7.6 Hz, 2H), 7.90 (s, 1H), 7.78-7.76 (d, J = 8.0 Hz, 2H), 7.69-7.67 (d, J = 8.0 Hz, 2H), 7.60-7.58 (m, 3H), 7.42-7.38 (m, 4H), 7.26 (m, 1H), 6.92-6.90 (d, J = 8.8 Hz, 2H), 6.08-6.04 (m, 1H), 3.82 (s, 3H), 3.73-3.65 (m, 1H), 3.17-3.12 (m, 1H); 13C NMR (100 MHz, CDCh): d 170.27, 165.08, 161.70, 155.43, 149.47, 139.73, 135.09, 134.75, 134.27, 132.52, 132.14, 131.72, 129.84, 129.33, 128.85, 128.45,128.06, 126.66, 126.01, 123.56, 122.45, 119.20, 114.27, 55.38, 53.48, 41.52, 29.69. ESIMS (m/z) for C33H26ClN404 +[M+H]+ : calculated 577.16, found 577.20.
[0269] Example 32-9a
[0270] l-benzyl-2-(l-(p-tolyl)ethylidene)hydrazine
[0271] NaOAc (1.64 g, 20 mmol) was slowly added to the mixture of benzylhydrazine dihydrochloride (2.32 g, 12 mmol) in ethanol (20 mL) at 0°C in an ice bath. The mixture was warmed to room temperature and then 4'-methylacetophenone (1.34 g, 10 mmol) was added. The mixture was stirred for 3h. The mixture was cooled to -l5°C, and the precipitate was filtered and washed with cold ethanol (15 mL). The filtrate was concentrated to dryness to give crude product as yellow oil (2.8 g), which was used for next steps without further purification. ESIMS (m/z) for CI6HI9N2 + [M+H]+ : calculated 239.15, found 239.10.
[0272] Example 33-9b
[0273] l-benzyl-3-(p-tolyl)-lH-pyrazole-4-carbaldehyde
[0274] This compound was prepared essentially by the method of Example 2 (yellow oil, 1.4 g, 41% yield for two steps). lH NMR (400 MHz, CDCh): d 9.84 (s, 1H), 7.85 (s, 1H), 7.56-7.54 (d, J = 8.0 Hz, 2H), 7.33-7.29 (m, 3H), 7.22-7.24 (m, 2H), 7.2l-7.l9(m, 2H), 5.28 (s, 2H), 2.34 (s, 3H). ESIMS (m/z) for CI8HI7N20 + [M+H]+ : calculated 277.13, found 277.10.
[0275] Example 34-9c
[0276] 3-(l-benzyl-3-(p-tolyl)-lH-pyrazol-4-yl)-l-(4-methoxyphenyl)-prop-2-en-l-one
[0277] This compound was prepared essentially by the method of Example 3. The product was purification by column chromatography (PE/EA=4:l) to give product as a light yellow solid (1.4 g, 63% yield). ¾ NMR (400 MHz, CDCb): d 7.90 (d, J = 8.0 Hz, 2H), 7.83-7.79 (d, J = 15.6 Hz, 1H), 7.53-7.51 (d, J = 8.0 Hz, 2H), 7.35-7.28 (m, 4H), 7.25-7.18 (m, 3H), 6.90-6.88 (d, J = 8.8 Hz, 2H), 5.32 (s, 2H), 2.38 (s, 3H). ESIMS (m/z) for C27H25N2O2 + [M+H]+ : calculated 409.18, found 409.20.
[0278] Example 35-9d
[0279] T-benzyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-3, 4-dihydro- TH,2H-3,4'-bipyrazole
[0280] This compound was prepared essentially by the method of Example 4. The mixture was evaporated to dryness to give crude product as light solid (1.4 g crude). 1 H NMR (400 MHz, CDCI3): d 7.93-7.91 (d, J = 8.4 Hz, 2H), 7.84-7.82 (d, J = 8.8 Hz, 2H), 7.74(s, 1H), 7.58-7,42 (m, 4H), 7.31-7.30 (m, 1H), 7.27-7.22 (m, 2H), 6.90-6.89 d, J = 8.8 Hz, 2H), 5.31 (s, 2H), 5.06- 5.01 (m, 1H), 3.82 (s, 3H), 3.40-3.30 (m, 1H), 2.96-2.91 (m, 1H), 2.38 (s, 3H). ESIMS (m/z) for C27H27N4O + [M+H]+ : calculated 423.21, found 423.20.
[0281] Example 36-9e
[0282] Methyl 3-(T-benzyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-3, 4-dihydro- TH,2H-[3, 4'- bipyrazole]-2- carbonyl)benzoate
[0283] This compound was prepared essentially by the method of Example 5 (85 mg, 31% yield). lH NMR (400 MHz, CDCb): d 8.74 (s, 1H), 8.18 (m, 2H) 7.62-7.61 (m, 2H) 7.56-7.51 (m, 3H), 7.36-7.31 (m, 4H), 7.28- 7.23 (m, 2H), 7.23-7.21 (d, J = 8.0 Hz, 2H), 6.91-6.88 (d, J = 8.8 Hz, 2H), 6.04-6.01 (m, 1H), 5.29 (s, 2H), 3.98 (s, 3H), 3.85 (s, 3H), 3.65-3.58 (m, 1H), 3.12-3.06 (m, 1H), 2.37 (s, 3H). ESIMS (m/z) for C36H33N4O4 + [M+H]+ : calculated 585.24, found 585.20.
[0284] Example 37-9
[0285] 3-(T-benzyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2- carbonyl)benzoic acid
[0286] This compound was prepared essentially by the method of Example 6. 1 H NMR (400 MHz, CDCI3): d 8.69 (s, 1H), 8.114-8.07 (m, 2H) 7.51-7.43 (m, 5H) 7.27-7.22 (m, 4H), 7.21 (m, 2H), 7.18-7.11 (m, 2H), 6.80-6.78 (d, J = 8.8 Hz, 2H), 5.94-5.92 (m, 1H), 5.20 (s, 2H), 3.73 (s, 3H), 3.55-3.48 (m, 1H), 3.02-2.96 (m, 1H), 2.27 (s, 3H). ESIMS (m/z) for C35H31N4C [M+H]+ : calculated 571.23, found 571.20.
[0287] Example 38-l0a
[0288] l-(4-methoxyphenyl)-2-(l-(p-tolyl)ethylidene)hydrazine
[0289] NaOAc (0.82 g, 10 mmol) was slowly added to the mixture of (4-methoxyphenyl) hydrazine hydrochloride (1.04 g, 6 mmol) in ethanol (20 mL) at 0°C in an ice bath. The mixture was warmed to room temperature and then 4'-methylacetophenone (0.67 g, 5 mmol) was added and the mixture was stirred for 3h. The mixture was cooled to -l5°C. The precipitate was filtered and washed with cold ethanol (15 mL) to give the product as a brown solid (1.03 g, 81% yield). lH NMR (400 MHz, CDCl3): d 7.88 (d, J = 7.2 Hz, 1H), 7.18-7.16 (d, J = 7.6 Hz, 4H), 7.13-7.12 (m, 2H), 6.88 (d, J = 7.6 Hz, 2H), 3.78 (s, 3H), 2.36 (s, 3H), 2.21 (s, 3H). ESIMS (m/z) for CI6HI9N20 + [M+H]+ : calculated 255.14, found 255.10.
[0290] Example 39-10b
[0291] l-(4-methoxyphenyl)-3-(p-tolyl)-lH-pyrazole-4-carbaldehyde
[0292] This compound was prepared essentially by the method of Example 2 (yellow solid, 410 mg, 35% yield). lH NMR (400 MHz, CDCb): d 10.02 (s, 1H), 8.42 (s, 1H), 7.71-7.67 (m, 4H), 7.31-7.26 (m, 2H), 7.01 (d, J = 9.2 Hz, 2H), 3.85 (s, 3H), 2.42 (s, 3H). ESIMS (m/z) for C18H17N2O2 + [M+H]+ : calculated 293.12, found 293.10.
[0293] Example 40-l0c
[0294] l-(4-methoxyphenyl)-3-(l-(4-methoxyphenyl)-3-(p-tolyl)-lH-pyrazol-4-yl)-prop-2-en- l-one
[0295] This compound was prepared essentially by the method of Example 3 (yellow solid, 424 mg, 71% yield). ¾ NMR (400 MHz, CDCI3): d 8.25 (s, 1H), 7.98-7.96 (d, J = 9.2 Hz, 2H), 7.89-7.86 (d, J = 15.6 Hz, 1H), 7.01-7.68 (d, J = 9.2 Hz, 2H), 7.61-7.59 (d, J = 8.0 Hz, 2H), 7.36-7.33 (d, J = 15.6 Hz, 1H), 7.30-7,28 (m, 2H), 7.02- 6.99 (d, J = 9.2 Hz, 1H), 6.97-6.94 (d, J = 8.8 Hz ,2H), 3.82 (m, 1H), 3.89 (s,3H), 3.87 (s, 3H), 2.43 (s, 3H). ESIMS (m/z) for C27H25N203 + [M+H]+ : calculated 425.18, found 425.20.
[0296] Example 4l-l0d
[0297] l'-(4-methoxyphenyl)-3', 5-di-p-tolyl-3, 4-dihydro- TH,2H-3,4'-bipyrazole
[0298] This compound was prepared essentially by the method of Example 4 (white solid, 310 mg, 73% yield). ¾ NMR (400 MHz, CDCb): d 7.91 (s, 1H), 7.71-7.58 (m, 6H), 7.28(m, 1H), 6.96-6.90 (m, 4H), 5.13-5.09 (m, 1H), 3.83 (s, 6H), 3.47-3.41 (m, 1H), 3.08-3.02 (m, 1H), 2.41 (s, 3H). ESIMS (m/z) for C27H27N4O + [M+H]+ : calculated 423.21, found 423.20.
[0299] Example 42-lOe
[0300] Methyl 3-(r,5-bis(4-methoxyphenyl)-3'-(p-tolyl)-3,4-dihydro-l'H,2H-[3,4'- bipyrazole]- 2-c arbonyl)benzoate
[0301] This compound was prepared essentially by the method of Example 5 (white solid, 286 mg, 65% yield). ¾ NMR (400 MHz, CDCb): d 8.80 (s, 1H), 8.22-8.17 (m, 2H), 7.77 (s, 1H), 7.69-7.67 (m, 2H), 7.59-7.52 (m, 5H), 7.23 (m, 1H), 6.92-6.88 (m, 4H), 6.11 (m, 1H), 3.96 (s, 3H), 3,83 (s, 3H), 3.81 (s, 3H), 3.68-3.61 (m, 1H), 3.17-3.11 (m,lH), 2.38 (s, 3H). ESIMS (m/z) for C36H33N4O5 + [M+H]+ :calculated 601.24, found 601.20.
[0302] Example 43-10
[0303] 3-(T, 5-bis(4-methoxyphenyl)-3'-(p-tolyl)-3, 4-dihydro- TH,2H-[3,4'-bipyrazole]-2- carbonyl)benzoic acid
[0304] This compound was prepared essentially by the method of Example 6 (white solid, 50 mg, 89% yield). ¾ NMR (400 MHz, CDCb): d 8.86 (s, 1H), 8.24-8.22 (d, J = 6.4 Hz, 2H), 7.78 (s, 1H), 7.78-7.68 (d, J = 8.0 Hz, 2H), 7.66-7.57 (m, 5H), 7.25 (m, 2H), 6.92-6.88 (m, 2H), 6.12-6.08 (m, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.68-3.62 (m,lH), 3.17-3.12 (m,lH), 2.38 (s, 3H). 13C NMR (100 MHz, CDCb): d 170.33, 165.04, 161.58, 158.27, 155.57, 150.18, 137.82, 135.14, 134.97, 133.73, 132.41, 132.18, 130.42, 129.30, 128.96, 128.46, 128.36, 128.01, 125.86, 123.77, 121.72, 120.83, 114.43, 114.16, 55.52, 55.37, 53.70, 41.47, 21.25. ESIMS (m/z) for C35H31N4O5 + [M+H]+ : calculated 587.22, found 587.20.
[0305] Scheme 4
[0306] Scheme 4 depicts a route for synthesizing compound 11.
[0307] Example 44-lle
[0308] Methyl 4-(5-(4-methoxyphenyl)-2'-phenyl-5'-(p-tolyl)-3,4-dihydro-2H,2'H-[3,3'- bipyrazol] -2-yl)benzoate
[0309] A mixture of methyl 4-bromobenzoate (54 mg, 0.25 mmol), 5-(4-methoxyphenyl)-2'- phenyl-5'-(p-tolyl)-3,4-dihydro-2H,2'H-3,3'-bipyrazole (100 mg, 0.25 mmol), Pd2(dba)3 (46 mg, 0.05 mmol), xPhos (46 mg, 0.1 mmol), and CS2CO3 (163 mg, 0.5 mml) in anhydrous dioxane (25 mL) under N2 was refluxed for 3 h. The solvent was removed. EtOAc (20 mL ) was added. The mixture was washed with water and brine. The organic phase was dried with Na2S04, filtered and concentrated. The residue was purified by prep.-HPLC to give the desired product as white solid (30.4 mg, 22.4 %yield). lH NMR (400 MHz, CDCI3): d 7.86 (d, J = 8.8 Hz, 2H), 7.70-7.66 (m, 5H), 7.60 (m, 2H), 7.38-7.34 (m, 4H), 7.25-7.19 (m, 1H), 7.03 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 5.60-5.55 (m, 1H), 3.84 (m,lH), 3.83 (s, 6H), 2.31-2.25 (dd, J = 16.8 Hz, 5.6 Hz,IH), 2.45 (s, 3H). ESIMS (m/z) for C34H34N4O3 + [M+H]+ : calculated 543.23, found 543.2.
[0310] Example 45-11
[0311] 4-(5-(4-methoxyphenyl)-2'-phenyl-5'-(p-tolyl)-3,4-dihydro-2H,2'H-[3,3'-bipyrazol]-2- yl)benzoic acid
[0312] 11 was synthesized by the same method as 1. *H NMR (400 MHz, DMSO-d6): d 8.27 (s, 1H), 7.83-7.81 (d, J = 8.0 Hz, 2H), 7.73-7.67 (m, 6H), 7.45-7.41 (m, 2H), 7.34-7.32 (d, J = 7.6 Hz, 2H), 7.28-7.24 (t, J = 7.6 Hz, 1H), 7.02-6.96 (m, 4H), 5.64-5.60 (m, 1H), 4.08-4.01 (m, 1H), 3.80 (s, 3H), 3.32 (m, 1H), 2.38 (s, 3H). ESIMS (m/z) for C33H29N4O3 + [M+H]+ : calculated 529.22, found 529.2.
[0313] Example 46-l2a
[0314] (E)-3-(2-(l-(p-tolyl) ethylidene) hydrazinyl) pyridine
[0315] Crude l2a (2.5 g without purification) was synthesized by the same method as la. ESIMS (m/z) for CI4HI6N3 + [M+H]+: calculated 226.3, found 226.2.
[0316] Example 47-12b
[0317] l-(pyridin-3-yl)-3-(p-tolyl)-lH-pyrazole-4-carbaldehyde
[0318] l2b (570 mg) was synthesized by the same method as lb. ESIMS (m/z) for Ci6Hi4N30+ [M+H]+: calculated 264.3, found 264.1.
[0319] Example 48- l2c
[0320] (E)-l-(4-methoxyphenyl)-3-(l-(pyridin-3-yl)-3-(p-tolyl)-lH-pyrazol-4-yl) prop-2-en-l- one (l2c) l2c (410 mg, 48% yield) was synthesized by the same method as lc. 1 H NMR
(400MHz, CDC13) : d 9.08 (s, 1H), 8.60 (d, J = 4.8 Hz, 1H), 8.37 (s, 1H), 8.17 (d, J = 8.0 Hz,
1H), 7.98 (d, J = 8.8 Hz, 2H), 7.86 (d, J =15.6 Hz, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.43-7.46 (m, 1H), 7.39 (d, J =15.6 Hz, lH),7.3l (d, J = 4.4 Hz, 2H), 6.96 (d, J = 8.4 Hz, 2H), 3.88 (s, 3H), 2.43 (s, 3H). ESIMS (m/z) for C25H22N302 + [M+H]+: calculated 396.5, found 396.1.
[0321] Example 49-l2d
[0322] (5-(4-methoxyphenyl)-r-(pyridin-3-yl)-3'-(p-tolyl)-3,4-dihydro-rH, 2H-3, 4'-bipyrazole
[0323] l2d (270 mg, 63% yield) was synthesized by the same method as ld. ESIMS (m/z) for C25H24N50+ [M+H]+: calculated 410.5, found 410.2.
[0324] Example 50-l2e
[0325] Methyl 3-(5-(4-methoxyphenyl)-r-(pyridin-3-yl)-3'-(p-tolyl)-3, 4-dihydro-l'H, 2H-[3, 4'-bipyrazole] -2-carbonyl) benzoate
[0326] l2e (62 mg, 45% yield) was synthesized by the same method as le. ESIMS (m/z) for C34H3ON504+ [M+H]+: calculated 572.6, found 572.2.
[0327] Example 51-12
[0328] 3-(5-(4-methoxyphenyl)-l’-(pyridin-3-yl)-3’-(p-tolyl)-3, 4-dihydro-l’H, 2H-[3, 4’- bipyrazole] -2-carbonyl) benzoic acid
[0329] 12 (35 g, 57% yield) was synthesized by the same method as 1. *H NMR (400 MHz, d6- DMSO) : d 9.15 (s, 1H), 8.65 (s, 1H), 8.50 (s, 2H), 8.28 (d, J = 8.0 Hz, 1H), 8.08 (t, J = 8.0 Hz, 2H), 7.50-7.74 (m, 6H), 7.32 (d, J = 8.0 Hz, 2H), 7.00 (d, J = 8.0 Hz, 2H), 7.88-7.92 (m, 1H), 3.92-3.99 (m, 1H), 3.79 (s, 3H), 3.25-3.27 (m, 1H), 2.38 (s, 3H). 13C NMR (100 MHz, d6- DMSO) : <5 161.5, 155.6, 151.1, 147.6, 140.3, 138.1, 135.4, 131.8, 131.1, 130.3, 129.7, 128.9, 128.6, 127.5, 126.1, 124.6, 124.3, 124.1, 114.7, 55.8, 53.5, 42.3, 21.4. ESIMS (m/z) for C33H28N5CV [M+H]+: calculated 558.6, found 558.2.
[0330] Example 52-l3a
[0331] (E)-l-(l-(4-methoxyphenyl) ethylidene)-2-phenylhydrazine
[0332] l3a (6.8 g, 85% yield) was synthesized by the same method as la. ESIMS (m/z) for CI5HI7N20+ [M+H]+: calculated 241.3, found 241.2.
[0333] Example 53-l3b
[0334] 3-(4-methoxyphenyl)- l-phenyl- lH-pyrazole-4-carbaldehyde
[0335] l3b (3.1 g, 89% yield) was synthesized by the same method as lb. 1 H NMR (400MHz,
CDCI3): d 10.04 (s, 1H), 8.52 (s, 1H), 7.78-7.81 (m, 4H), 7.49-7.53 (m, 2H), 7.39 (t, J = 7.6 Hz,
1H), 7.03 (d, J = 8.8 Hz, 2H), 3.88 (s, 3H). ESIMS (m/z) for Ci7Hi5N202 + [M+H]+: calculated
279.3, found 279.1.
[0336] Example 54-13c
[0337] (E)-l-(4-methoxyphenyl)-3-(3-(4-methoxyphenyl)-l-phenyl-lH-pyrazol-4-yl) prop-2- en-l-one
[0338] l3c (2.3 g, 77% yield) was synthesized by the same method as lc. ESIMS (m/z) for C26H23N2C>3 + [M+H]+: calculated 411.5, found 411.1.
[0339] Example 55-13d
[0340] 3', 5-bis (4-methoxyphenyl)-l'-phenyl-3, 4-dihydro-l'H, 2H-3, 4'-bipyrazole
[0341] l3d was synthesized by the same method as ld. ESIMS (m/z) for C26H25N402 + [M+H]+: calculated 425.5, found 425.2.
[0342] Example 56-l3e
[0343] Methyl 3-(3', 5-bis-(4-methoxyphenyl)-l'-phenyl-3, 4-dihydro-l'H, 2H-[3, 4'- bipyrazole] -2-carbonyl) benzoate l3e (58 mg, 41% yield) was synthesized by the same method as le. ESIMS (m/z) for C35H3iN405+ [M+H]+: calculated 587.7, found 587.1.
[0344] Example 57-13
[0345] 3-(3', 5-bis-(4-methoxyphenyl)-r-phenyl-3, 4-dihydro-l'H, 2H-[3, 4'-bipyrazole]-2- carbonyl) benzoic acid
[0346] 13 (31 mg, 54% yield) was synthesized by the same method as 1. 1 H NMR (400MHz, de-DMSO) : d 8.51 (s, 2H), 8.09 (t, J = 8.8 Hz, 2H), 7.88 (d, J = 8.0 Hz, 2H), 7.76 (d, J = 8.0 Hz, 2H), 7.64 (d, J = 8.4 Hz, 2H), 7.58 (t, J = 7.6 Hz, 1H), 7.46 (t, J = 7.6 Hz, 2H), 7.27 (d, J = 7.2 Hz, 1H), 7.05 (d, J = 8.4 Hz, 2H), 7.05 (d, J = 8.4 Hz, 2H), 7.00 (d, J = 8.4 Hz, 2H), 5.86- 5.90 (m, 1H), 3.90-3.97 (m, 1H), 3.82 (s, 3H), 3.79 (s, 3H), 3.23-3.29 (m, 1H). 13C NMR (100 MHz, de-DMSO) : <5 165.1, 161.5, 159.7, 155.6, 150.1, 139.9, 135.4, 133.9, 131.8, 131.0, 129.9, 129.9, 128.9, 128.3, 126.9, 126.5, 125.9, 124.2, 123.5, 118.6, 114.7, 114.5, 55.8, 55.7, 53.6,
42.3. ESIMS (m/z) for C34H29N405 + [M+H]+: calculated 573.6, found 573.2.
[0347] Scheme 5
[0348] Scheme 5 depicts a route for synthesizing compound 14.
[0349] Example 58-l4a
[0350] 3-(5-(4-methoxyphenyl)-r-phenyl-3'-(p-tolyl)-3,4-dihydro-rH, 2H-[3, 4'-bipyrazole]-2- carbonyl) benzonitrile
[0351] Using ld as starting material, l4a (75 mg, 57% yield) was synthesized by the same method as le. ESIMS (m/z) for C34H2sN 02 + [M+H]+: calculated 538.6, found 538.3.
[0352] Example 59-14
[0353] (3-(lH-tetrazol-5-yl) phenyl) (5-(4-methoxyphenyl)-l'-phenyl-3'-(p-tolyl)-3, 4-dihydro- GH, 2H-[3, 4'-bipyrazol]-2-yl) methanone
[0354] A mixture of l4a (75 mg, 0.14 mmol), NaN3 (90 mg, 1.39 mmol), CuS04.5H20 (35 mg, 0.14 mmol), in DMSO (3 mL) in sealed tube was heated to l40°C under N2, and stirred for 5 hours and then cooled to rt. To the reaction mixture was filtered and the filtrate was purified by prep. HPLC to give 14 (22 mg, 27%yield). Ή NMR (400MHz, CDC13 ) : d 8.64 (s, 1H), 8.09- 8.21 (m, 2H), 7.90 (s, 1H), 7.50-7.59 (m, 7H), 7.29-7.33 (m, 2H), 7.11-7.19 (m, 3H), 6.84 (d, J = 8.0 Hz, 2H), 6.11-6.14 (m, 1H), 3.79 (s, 3H), 3.61-3.68 (m, 1H), 3.12-3.17 (m, 1H), 2.29 (s, 3H).13C NMR (lOOMHz, CDCI3) : d 161.8, 139.6, 138.1, 134.9, 132.7, 130.2, 129.9, 129.3, 128.6, 128.2, 126.5, 125.8, 124.2, 123.3, 121.6, 119.0, 114.2, 55.4, 41.6, 21.2. ESIMS (m/z) for C34H29N802 + [M+H]+: calculated 581.6, found 581.2.
[0355] Scheme 6
[0357] Example 60-l5a
[0358] (E)-l-(l-(4-bromophenyl) ethylidene)-2-phenylhydrazine
[0359] l5a (5.1 g, 70% yield as orange solid) was synthesized by the same method as la. ESIMS (m/z) for Ci4Hi4BrN2 + [M+H]+: calculated 289.0, 291.0 found 289.0, 291.0.
[0360] Example 6l-l5b
[0361] 3 -(4-bromophenyl)- 1 -phenyl- lH-pyrazole-4-carbaldehyde
[0362] l5b (1.7 g, 75% yield) was synthesized by the same method as lb. 1 H NMR (400MHz, CDCl3): d 10.04 (s, 1H), 8.53 (s, 1H), 7.76-7.80 (m, 4H), 7.64 (d , J = 8.4 Hz, 2H), 7.53 (t, J = 7.6 Hz, 2H), 7.41 (t, J = 7.6 Hz, 1H). ESIMS (m/z) for Ci6Hi2BrN20+ [M+H]+: calculated 327.0, 329.0 found 327.0, 329.0.
[0363] Example 62-15c
[0364] (E)-3-(3-(4-bromophenyl)-l-phenyl-lH-pyrazol-4-yl)-l-(4-methoxyphenyl) prop-2-en- l-one
[0365] l5c (1.1 g, 79% yield) was synthesized by the same method as lc. ESIMS (m/z) for C25H20BrN2O2 + [M+H]+: calculated 459.0, 461.0 found 459.0, 461.0.
[0366] Example 63-l5d
[0367] 3'-(4-bromophenyl)-5-(4-methoxyphenyl)-l'-phenyl-3, 4-dihydro-l'H, 2H-3, 4'- bipyrazole
[0368] l5d (730 mg, 73% yield) was synthesized by the same method as ld. ESIMS (m/z) for C25H22BrN40+ [M+H]+: calculated 473.1, 475.1 found 473.0, 475.1.
[0369] Example 64-l5e
[0370] Methyl 3-(3'-(4-bromophenyl)-5-(4-methoxyphenyl)-l'-phenyl-3, 4-dihydro-l'H, 2H-[3, 4'-bipyrazole] -2-carbonyl) benzoate
[0371] l5e (162 mg, 61% yield) was synthesized by the same method as le. 1 H NMR (400MHz, CDCI3) : d 8.80 (s, 1H), 8.19 (t, J = 7.2 Hz, 2H), 7.89 (s, 1H), 7.66-7.71 (m, 4H),
7.52-7.60 (m, 5H), 7.40 (t, J = 7.2 Hz, 2H), 7.24-7.27 (m, 1H), 6.91 (t, J = 8.4 Hz, 2H), 6.04 (d, J = 7.6 Hz, 1H), 3.96 (s, 3H), 3.84 (s, 3H), 3.63-3.70 (m, 1H), 3.10-3.15 (m, 1H). ESIMS (m/z) for C34H28BrN404+ [M+H]+: calculated 635.1, 637.1 found 635.1, 637.1.
[0372] Example 65- l5f
[0373] Methyl 3-(5-(4-methoxyphenyl)-r-phenyl-3'-(4-(l-((2-(trimethylsilyl) ethoxy) methyl)- lH-imidazol-4-yl) phenyl)-3, 4-dihydro-l'H, 2H-[3, 4'-bipyrazole] -2-carbonyl) benzoate
[0374] A mixture of l5e (100 mg, O.l6mmol), l-((2-(trimethylsilyl) ethoxy) methyl)-lH- imidazole (63 mg, 0.32 mmol), Pd (OAc) 2 (7 mg, 0.08 mmol), KOAc (31 mg, 0.32 mmol) in DMF (lmL) was added in sealed tube and then heated to l40°C under N2 atm.. After 5h, the reaction mixture was cooled to room temperature and pured into water (5 mL). The mixture extracted with EA (5mL*2). The organic phase was washed with brine, dried over Na2S04, and filtered. The filtrate was concentrated. The residue was purified by prep. TLC (EA) to give l5f (48 mg, 40% yield). ESIMS (m/z) for C43H45N6O5SP [M+H]+: calculated 753.3, found 753.3.
[0375] Example 66-15
[0376] 3-(3'-(4-(lH-imidazol-4-yl) phenyl)-5-(4-methoxyphenyl)-T-phenyl-3, 4-dihydro-l'H, 2H-[3, 4'-bipyrazole]-2-carbonyl) benzoic acid
[0377] A mixture of l5f (48 mg, 0.064 mmol) and L1OH.H2O (27 mg, 0.64 mmol) in dioxane/water (lmL/lmL) was heated to 45°C and stirred for 1 hours. The reaction mixture was cooled to room temperature and acidified to pH=6 by 1 M HC1. The reaction mixture was extracted with EA (l0mL*2). The organic phase was washed with brine, dried over Na2S04, and filtered. The filtrate was concentrated. The residue was dissolved in DCM (1 mL). TFA (1 mL) was added the mixture. The resulting mixture was heated to 45 °C and stirred for 3 hours. The reaction mixture was concentrated and the residue was purified by prep. HPLC to give 15 (18 mg, 46% yield). lH NMR (400MHz, d6-DMSO) : d 8.53-8.55 (m, 2H), 8.08-8.17 (m, 2H), 7.85-7.92 (m, 7H), 7.59-7.71 (m, 4H), 7.47 (t, J = 8.0 Hz, 2H), 7.29 (t, J = 7.6 Hz, 1H), 7.00 (d, J = 8.8 Hz, 2H), 5.94-5.98 (m, 1H), 3.96-4.03 (m, 1H), 3.79 (s, 3H), 3.28-3.34 (m, 1H). 13C NMR (100 MHz, d6-DMSO) <5167.4, 164.9, 161.5, 155.8, 150.0, 139.9, 135.6, 134.4, 131.8, 131.3, 131.1, 130.8, 129.9, 128.9, 128.7, 128.5, 127.0, 126.7, 125.0, 124.1, 123.8, 118.7, 114.7, 55.8, 53.7, 42.4. ESIMS (m/z) for C36H29N6CV [M+H]+: calculated 609.7, found 609.2.
[0378] Protein Expression and Purification
[0379] The plasmid of p ET 28 a - C a v 2.2 b 3 subunit was transformed into competent E. Coli BL2l(DE3) strain. Culture was grown in LB medium at 37°C to an OD600 of approximately 0.6 and then induced with 0.5 mM IPTG at 16 °C for 16 h. Cells were collected by centrifugation and lysed by microfluidizer in lysis buffer (phosphate buffer, pH 7.6, 2 mM DTT). The His-Cav 3 protein was purified at 4 °C using Ni-IMAC chromatography (His-Trap HP, GE Healthcare) and eluted with 500 mM imidazole in lysis buffer with a gradient method. After the fractions consisted of His-Cav 3 was combined and concentrated, the protein was further purified using size exclusion chromatography (Superdex 200 pg, GE Healthcare) in PBS with 2 mM DTT.
[0380] Label-Free Microscale Thermophoresis
[0381] Direct binding of compound 6 to Cav 3 was confirmed with label-free microscale thermophoresis (MST). Raw data was used to generate a binding curve that led to a dissociation (Kd) of 3.6 ± 1.1 mM.
[0382] Site-Directed Mutagenesis
[0383] Compound 6 forms a salt bridge interaction with Arg-307 through a benzoic acid moiety. The removal of the charge, such as in compound 7, led to complete loss of inhibition of the CaVal »CaVp3 interaction. Arg-307 was mutated to alanine. The resulting Cav 3 Arg-307- Ala mutant binds to CaVal-AiD with a Kd of 240 ± 59 nM, a nearly lO-fold reduction.
[0384] Surface Biotinylation Assay
[0385] Cell-surface protein biotinylation and western blotting were performed. Briefly,
HEKCav2.2 cells were treated with compound 6 or the vehicle (DMSO) for 48 hours. The surface proteins were biotinylated with 5 mM biotin-X-NHS (EMD Millipore, Billerica, MA) in
PBS for 30 min at 4°C. After biotinylation, cells were quenched and washed with PBS containing 100 mM glycine. Then, cells were lysed in ice-cold RIPA buffer containing the Halt protease inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA). The lysate was cleared by centrifugation, the pre-absorbed avidin-agarose beads were added, and the resulting suspension was rotated for 30 min at 4°C. The avidin-agarose beads were spun down and then washed 3 times with the complete lysis buffer. Proteins were eluted from the beads by incubating with SDS gel loading buffer supplemented with 1 mM DTT for 10 min at 70°C. The eluted proteins were separated using 10% SDS-polyacrylamide gel electrophoresis, transferred onto polyvinylidene difluoride membrane (PVDF) (Immun-Blot, Bio-Rad), and probed with the anti-Cav2.2-alB antibody from Alomone Labs (1:1000 dilution; Israel, Cat. #: AC002) and the
Na+, K+-ATPase antibody (1:1000 dilution; Cell Signaling, Cat.#30l0). Compound 6 at 50 mM, significantly decreased surface presentation of the Cav2.2al subunit.
[0386] Patch Clamp Technique
[0387] The whole cell patch-clamp technique was used to record Cav2.2 currents in HEK- Cav2.2 cells and rat DRG neurons. HEK293 cells that stably expressed rat N-type CaV2.2alB, rat CaV 3, and rat a2d-1 were utilized. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 50 units penicillin, 50 pg/ml streptomycin, 5 pg/ml blasticidin, 5 pg/ml hydromycin and 25 pg/ml zeozin at 37 °C in a humidified atmosphere of 95% air and 5% C02. For patch clamp experiments, HEK-Cav2.2 cells were plated on glass coverslips and were cultured for 24-48 h. All animal procedures were performed in accordance to the NIH guide and were approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee. Young adult Sprague Dawley rats were anesthetized (3% isoflurane) and then decapitated. The spinal column was removed, cut open, and dorsal root ganglia were harvested from the Lumbar L4-L6 vertebral levels. The ganglia were incubated in DMEM containing collagenase (1 mg/ml, Worthington: LS04194) and protease (1 mg/ml, Worthington: LS02104) for 30-60 minutes, and DRG neurons were dissociated by triturating in DMEM supplemented with 10% FBS. The isolated DRG neurons were plated on glass coverslips coated with growth factor reduced Matrigel (Thermo Fisher Scientific, Waltham, MA) and were cultured in Eagle's minimum essential medium (Invitrogen, CA) supplemented with 0.2% BSA and 20 ng/ml NGF-2.5S (BD Biosciences, Bedford, MA) at 37°C in a water- jacketed 5% CO2 incubator overnight for the patch-clamp experiments.
[0388] Cav2.2 currents were recorded in HEK-Cav2.2 cells pretreated with 10, 25, and 50 pM of compound 6 for 48 hours. The current densities obtained in the cells treated with 50 pM compound 6 were significantly decreased compared with vehicle DMSO group (IDMSO= -98.0
± 12.5 pA/pF, n = 12 vs 16= -28.7 ± 5.0 pA/pF, n = 15, *p < 0.001). G-V curves for CaV2.2 were shifted towards more positive potentials in HEK-Cav2.2 cells pretreated with compound 6 for 48 hours. The mean half-activation potential was greater in the cells compared to the control cells pretreated with DMSO for 48 hours (DMSO: 6.7 ± 0.6 mV, n = 14; compound 6:
9.4 ± 1.2 mV, n = 14, p < 0.05). Conversely, acute application of 50 pM compound 6 did not affect Cav2.2 currents either in HEK-Cav2.2 cells or in rat DRG neurons, indicating that the compound does not inhibit the channel pore directly. Compound 2 did not affect the Cav2.2 currents amplitudes in HEK-Cav2.2 cells when it was used acutely or as a long-term treatment.
[0389] When activated by depolarizing pulses to 0 mV from a holding potential of -80 mV, the density of Cav2.2 currents were significantly smaller in HEK-Cav2.2 cells pretreated for 48
hours with 50 mM compound 14 than in cells treated with 50 mM compound 2 or DMSO (48 hours; compound 15: -11.1 ± 2.4 pA/pF, n = 12, compound 2: -79.2 ± 8.2 pA/pF, n = 9; DMSO: -74.8 ± 7.0 pA/pF, n = 15; p < 0.001). The apparent IC50 for inhibition of Cav2.2 currents by compound 14 is 31 mM.
[0390] The CaV2.2 steady-state inactivation curves were significantly shifted towards more positive potentials in HEK-CaV2.2 cells pretreated for 48 hours with compound 14 (50 mM, V0.5, inact= -52.9 ± 1.3 mV, p < 0.005, n = 10) compared with the control group (compound 2; 50 mM, V0.5, inact= -61.6 ± 2.0 mV, n = 10). The mean half-activation potential for Cav2.2 channels exhibited a more positive value in HEK-Cav2.2 cells pretreated for 48 hours with compound 14 (50 mM, V0.5, act = 16.5 ± 1.1 mV, p < 0.001, n = 12) compared with the controls (DMSO: V0.5, act = 8.7 ± 1.1 mV, n=l2; compound 2: 50 mM, V0.5, act = 8.5 ± 1.4 mV, n = 9).
[0391] No significant change in the mean half-activation voltage value was observed in patch- clamped HEK-Cav2.2 cells acutely treated with DMSO (Before: V0.5, act = 9.1 ± 1.6 mV; 5 min under DMSO: V0.5, act = 6.8 ± 3.3 mV, n = 3, p > 0.05). Conversely, a five-minute incubation with 50 mM compound 14 was sufficient to significantly shift the G-V curves of Cav2.2 towards more positive potentials (Before: V0.5, act = 6.4 ± 1.9 mV; 5 min under compound 15: V0.5, act = 11.4 ± 1.7 mV, n = 7, p < 0.01) indicating that the Cav2.2 channel requires a stronger depolarization to be activated in the presence of compound 14.
[0392] Animal Use
[0393] Pathogen-free, adult, female Sprague Dawley (weight at testing 150-200 g; Harlan- Sprague-Dawley, Indianapolis, IN) were housed in a climate-controlled room on a l2-hour light/dark cycle and were allowed to have food and water ad libitum. All procedures were approved by the Indiana University Animal Care and Use Committee and conformed to the guidelines of the National Institutes of Health (publication no. 80-23, 1966) for the use of laboratory animals. All behavioral experiments were conducted by experimenters blinded to the treatment conditions and compound identity. The experiments were replicated a minimum of 2 times with independent cohorts of animals.
[0394] For in vivo studies, the inventive compounds were freshly prepared saline (0.9%) on the day of the experiment. Morphine sulfate salt (Sigma- Aldrich, St. Louis, MO) was freshly prepared on the day of the experiment in saline. All drugs were dissolved in 1 mL solution and administered by intraperitoneal (i.p.) injections 1 h prior to all behavioral assays.
[0395] Plasma concentrations at various time points were determined using liquid chromatography tandem mass spectroscopy (LC-MS/MS). For intravenous (IV) administration,
compound 14 was formulated as a solution at a final dose of 1 mg/kg. The elimination half-life of compound 14 was 0.29 hours. The Tmax in plasma was 0.083 hours, and the Cmax peak plasma concentration was 181.36 ng/ml. The AUC 0-t concentration was 57.99 ng/ml*h.
[0396] For oral gavage (PO) administration, compound 14 was formulated as a solution at a final dose of 10 mg/kg. Plasma concentrations at various time points were determined using LC-MS/MS. The elimination half-life of compound 14 was 1.99 hours. The Tmax in plasma was 1 hour, and the Cmax peak plasma concentration was 164.7 ng/ml. The AUC 0-t concentration was 635.555 ng/ml*h.
[0397] Acute Thermal Nociception in the Rat
[0398] To evaluate the PWT to thermal stimulation, the Hargreaves' plantar test apparatus (Ugo Basile, Varese, Italy) was used. Measurements of the withdrawal latency of the paw began after the rats were habituated to the testing environment (IR setting = 70). The measurements were repeated four times, at 5 min intervals and the initial pair of measurements was not used. The averages of the three remaining pairs of measurements taken were employed as data.
[0399] A model of behavioral sensitivity using thermal stimulus was used to determine the acute analgesic properties of the compounds of the present invention. Systemic administration of compound 6 failed to elicit changes in the response latency at 1 or 10 mg/kg.
[0400] Neuropathic Pain Attenuation
[0401] The inventive compounds were assessed with the tibial nerve injury (TNI) model of neuropathic pain 28 days after surgery. Using isoflurane anesthesia (4% induction and 2% maintenance), the right sciatic nerve was isolated under aseptic surgical conditions by blunt dissection of the femoral biceps muscle and the tibial nerve was tightly ligated with 5-0 silk and transected distal to the ligation. Additional 2 to 3 mm of distal nerve stump was removed to prevent reinnervation by the proximal nerve. The overlying muscle and skin was then sutured in 2 separate layers. Sham-injured animals were subjected to all preceding procedures with the exception of ligation and transection. All animals were returned to the housing facility and allowed to survive for 28 d. Mechanical stimuli were applied with 7 filaments, each differing in the bending force delivered (10, 20, 40, 60, 80, 100, and 120 mN), and fitted with a flat tip and fixed diameter of 0.2 mm. The filaments were tested in the order of ascending force, with each filament delivered for 1 second. Withdrawal threshold was determined by sequentially increasing and analyzed with Hill equation was fitted to the function (Origin version 6.0; Microcal Software) relating the percentage of indentations eliciting a withdrawal to the force of indentation.
[0402] Before administration, all injured animals exhibited pronounced mechanical allodynia (33.1 ± 5.9 mN; n = 8-10) in response to von Frey hair stimulation of the injured hind paw, compared with pre-surgery levels, which averaged 68.7 ± 3.7 mN ( n = 8-10). Pronounced attenuation of tactile hypersensitivity was observed at 1 h but not at 4 h after systemic administration of compound 6 (10 mg/kg, ip; 62.2 ± 3.1 mN; n = 16). Compound 6 dosing levels of 1 mg/kg and 0.1 mg/kg did not alter behavior at 1 or 4 hours. In contrast, systemic administration of morphine (5 mg/kg) and compound 2 (10 mg/kg, ip) were ineffective at reducing hypersensitivity, with levels averaging 32 ± 2.6 mN ( n = 8). That PWT returned to baseline by 4 hours in compound 6-injected rats is consistent with the turnover of drug over this period. Rats 28 days after TNI exposed to compound 14 (0.1 mg/kg) significantly increased PWTs at both 1 and 24 hours post-injection compared to compound 6 and vehicle control.
[0403] Pharmacokinetic s
[0404] PK profiles of compound 14 after intravenous and oral administration was performed in Kunming mice. Plasma concentrations were determined by liquid chromatography tandem mass spectroscopy. Summary of PK properties and plasma concentration measured 1 hour after intravenous or oral administration of 1 or 10 mg/kg compound 14.
[0405] Other variations or embodiments will be apparent to a person of ordinary skill in the art from the above-description. Thus, the foregoing embodiments are not to be construed as limiting the scope of the claimed invention.
Claims
1. A compound of Formula (la)
wherein
Rla is C(0)R 1 or phenyl optionally substituted with one or more -CO2H, -C(0)0Ci-C4 alkyl, or heteroaryl, wherein R1 is -C1-C4 alkyl-CCLH, -C1-C4 alkyl-C(0)Ci-C4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)0Ci-C4 alkyl, or heteroaryl;
R2 is phenyl, heteroaryl, -C1-C4 alkyl-phenyl, or -C1-C4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with Ci-C4alkoxy;
R3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C3 alkyl, halo, -Ci-C4 alkoxy, or heteroaryl; and
R4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy, piperazinyl, or heteroaryl;
with the proviso that the compound of Formula (la) is not
or a pharmaceutically acceptable salt thereof.
2. A compound of Formula (1)
R1 is selected from the group consisting of (C1-C4 alkyl)-C02H, and -CO2H and tetrazole substituted phenyl;
R2 is selected from the group consisting of phenyl, methoxy substituted phenyl, and pyridinyl;
R3 is selected from the group consisting of (C1-C3 alkyl) substituted phenyl and halo substituted phenyl; and
R4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridyl;
with the proviso that the compound of Formula (1) is not
3. The compound or pharmaceutically acceptable salt thereof of claim 1 or claim 2, wherein R1 is selected from the group consisting of -CO2H substituted phenyl, tetrazole substituted phenyl, and -(CH2)2C02H.
4. The compound or pharmaceutically acceptable salt thereof of claim 1 or claim 2, wherein R1 is (CH2)2C02H.
5. The compound or pharmaceutically acceptable salt thereof of claim 1 or 2, wherein R2 is phenyl, methoxy substituted phenyl, or heteroaryl.
6. The compound or pharmaceutically acceptable salt thereof of claim 1 or 2, wherein R2 is phenyl.
7. The compound or pharmaceutically acceptable salt thereof of claim 6, wherein R2 is methoxy substituted phenyl.
8. The compound or pharmaceutically acceptable salt thereof of claim 1 or 2, wherein R3 is methyl-phenyl or chloro-phenyl.
9. The compound or pharmaceutically acceptable salt thereof of claim 1 or 2, wherein R4 is methoxy-phenyl or phenyl pyridyl.
10. The compound or pharmaceutically acceptable salt thereof of claim 1 or 2 that is selected from the group consisting of 4-(r-isopropyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-lH,TH-[3,4'- bipyrazol]-2(5H)-yl)-4-oxobutanoic acid, 3-(3'-(4-chlorophenyl)-5-(4-methoxyphenyl)-r- phenyl-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, 3-(l',5-bis(4- methoxyphenyl)-3'-(p-tolyl)-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, and 3-(3'-(4-methylphenyl)-5-(4-methoxyphenyl)-r-phenyl-3,4-dihydro-rH,2H-[3,4'-bipyrazole]-2- tetrazole.
11. A pharmaceutical composition comprising a compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier, diluent or excipient.
12. A method to treat a neurological disorder in a mammal in need thereof, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof of a compound of Formula (la)
wherein
Rla is C(0)R1 or phenyl optionally substituted with one or more -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl, wherein R1 is -C1-C4 alkyl-CCkFl, -C1-C4 alkyl-C(0)Ci-C4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)OCi-C4 alkyl, or heteroaryl;
R2 is phenyl, heteroaryl, -C1-C4 alkyl-phenyl, or -C1-C4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy;
R3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C3 alkyl, halo, -C1-C4 alkoxy, or heteroaryl; and
R4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy, piperazinyl, or heteroaryl;
or a pharmaceutically acceptable salt thereof.
13. A method to treat a neurological disorder in a mammal in need thereof, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof of a compound of of Formula (1)
wherein
R1 is selected from the group consisting of -(C1-C4 alkyl)-C02H, and -C02H and tetrazole substituted phenyl;
R2 is selected from the group consisting of phenyl, methoxy substituted phenyl, and pyridinyl;
R3 is selected from the group consisting of (C1-C3 alkyl) substituted phenyl and halo substituted phenyl; and
R4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridyl.
14. The method of claim 12 or 13, wherein the neurological disorder is pain.
15. The method of claim 12 or 13, wherein R1 is selected from the group consisting of -CO2H substituted phenyl, tetrazole substituted phenyl, and -(Cth^CCkH.
16. The method of claim 12 or 13, wherein R1 is -(Cth^CCkH.
17. The method of claim 12 or 13, wherein R2 is phenyl, methoxy substituted phenyl, or heteroaryl.
18. The method of claim 12 or 13, wherein R2 is phenyl.
19. The method of claim 12 or 13, wherein R2 is methoxy substituted phenyl.
20. The method of claim 12 or 13, wherein R3 is methyl-phenyl or chloro-phenyl.
21. The method of claim 12 or 13, wherein R4 is methoxy-phenyl or phenyl substituted with pyridyl.
22. The method of claim 12 or 13, wherein the compound is selected from the group consisting of 4-(r-isopropyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-lH,l'H-[3,4'-bipyrazol]-2(5H)-yl)-4- oxobutanoic acid, 3-(3'-(4-chlorophenyl)-5-(4-methoxyphenyl)-r-phenyl-3,4-dihydro-l'H,2H- [3,4'-bipyrazole]-2-carbonyl)benzoic acid, 3-(r,5-bis(4-methoxyphenyl)-3'-(p-tolyl)-3,4- dihydro-l'H,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, and 3-(3'-(4-methylphenyl)-5-(4- methoxyphenyl)- 1 '-phenyl-3 ,4-dihydro- TH,2H- [3 ,4'-bipyrazole]-2-tetrazole.
23. A method to modulate a protein-protein interaction between pore and auxiliary subunits of a voltage-gated ion channel in a nerve cell, comprising contacting the nerve cell with an effective amount of the compound of Formula (la)
wherein
Rla is C(0)R1 or phenyl optionally substituted with one or more -CO2H, -C(0)0Ci-C4 alkyl, or heteroaryl, wherein R1 is -C1-C4 alkyl-C02H, -C1-C4 alkyl-C(0)Ci-C4 alkyl, or phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -CO2H, -C(0)0Ci-C4 alkyl, or heteroaryl;
R2 is phenyl, heteroaryl, -C1-C4 alkyl-phenyl, or -C1-C4 alkyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy;
R3 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C3 alkyl, halo, -C1-C4 alkoxy, or heteroaryl; and
R4 is phenyl, wherein each hydrogen atom in phenyl is independently optionally substituted with -C1-C4 alkoxy, piperazinyl, or heteroaryl;
or a pharmaceutically acceptable salt thereof.
24. A method to modulate a protein-protein interaction between pore and auxiliary subunits of a voltage-gated ion channel in a nerve cell, comprising contacting the nerve cell with an effective amount of the compound of Formula (1)
wherein
R1 is selected from the group consisting of- (C1-C4 alkyl)-C02H, and -C02H and tetrazole substituted phenyl;
R2 is selected from the group consisting of phenyl, methoxy substituted phenyl, and pyridinyl;
R3 is selected from the group consisting of (C1-C3 alkyl) substituted phenyl and halo substituted phenyl; and
R4 is selected from the group consisting of alkoxy substituted phenyl and phenyl substituted pyridyl.
25. The method of claim 23 or 24, wherein the pore forming subunit is CaVal.
26. The method of claim 23 or 24, wherein the the auxiliary subunit is CaV or a
pharmaceutically acceptable salt thereof.
27. The method of claim 23 or 24, wherein the neurological disorder is pain.
28. The method of claim 23 or 24, wherein R1 is selected from the group consisting of -CO2H substituted phenyl, tetrazole substituted phenyl, and -(Ctk^CCkH.
29. The method of claim 23 or 24, wherein R1 is -(Cth^CCkH.
30. The method of claim 23 or 24, wherein R2 is phenyl, methoxy substituted phenyl, or heteroaryl.
31. The method of claim 23 or 24, wherein R2 is phenyl.
32. The method of claim 23 or 24, wherein R2 is methoxy substituted phenyl.
33. The method of claim 23 or 24, wherein R3 is methyl-phenyl or chloro-phenyl.
34. The method of claim 23 or 24, wherein R4 is methoxy-phenyl or phenyl substituted with pyridyl.
35. The method of claim 23 or 24, wherein the compound is selected from the group consisting of 4-(r-isopropyl-5-(4-methoxyphenyl)-3'-(p-tolyl)-lH,l'H-[3,4'-bipyrazol]-2(5H)-yl)-4- oxobutanoic acid, 3-(3'-(4-chlorophenyl)-5-(4-methoxyphenyl)-l'-phenyl-3,4-dihydro-rH,2H- [3,4'-bipyrazole]-2-carbonyl)benzoic acid, 3-(l',5-bis(4-methoxyphenyl)-3'-(p-tolyl)-3,4- dihydro-rH,2H-[3,4'-bipyrazole]-2-carbonyl)benzoic acid, and 3-(3'-(4-methylphenyl)-5-(4- methoxyphenyl)- 1 '-phenyl-3 ,4-dihydro- TH,2H- [3 ,4'-bipyrazole]-2-tetrazole.
36. A compound selected from the group consisting of
pharmaceutically acceptable salt thereof.
37. The compound of claim 36, selected from the group consisting of
pharmaceutically acceptable salt thereof.
38. Use of a compound according to any one of claims 1-10, 36, or 37, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating a neurological disorder in a patient.
39. The use of claim 38, wherein the neurological disorder is pain.
40. A compound according to any one of claims 1-10, 36, or 37, or a pharmaceutically acceptable salt thereof, for treating a neurological disorder in a patient.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19862398.5A EP3852743A4 (en) | 2018-09-19 | 2019-09-19 | Pyrazolylacylpyrazoline compounds and method for treating pain |
US17/251,473 US20210155609A1 (en) | 2018-09-19 | 2019-09-19 | Pyrazolylacylpyrazoline compounds and method for treating pain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862733153P | 2018-09-19 | 2018-09-19 | |
US62/733,153 | 2018-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020061303A1 true WO2020061303A1 (en) | 2020-03-26 |
Family
ID=69887840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/051920 WO2020061303A1 (en) | 2018-09-19 | 2019-09-19 | Pyrazolylacylpyrazoline compounds and method for treating pain |
Country Status (3)
Country | Link |
---|---|
US (1) | US20210155609A1 (en) |
EP (1) | EP3852743A4 (en) |
WO (1) | WO2020061303A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130028989A1 (en) * | 2010-02-05 | 2013-01-31 | Indiana University Research And Technology Corporation | Materials and method for inhibiting replication protein a and uses thereof |
US20140323483A1 (en) * | 2007-11-07 | 2014-10-30 | University Of Massachusetts | Type iii secretion inhibitors, analogs and uses thereof |
WO2018001973A1 (en) * | 2016-06-29 | 2018-01-04 | Laboratorios Del Dr. Esteve S.A. | Pyrazole derivatives having activity against pain |
-
2019
- 2019-09-19 US US17/251,473 patent/US20210155609A1/en active Pending
- 2019-09-19 WO PCT/US2019/051920 patent/WO2020061303A1/en unknown
- 2019-09-19 EP EP19862398.5A patent/EP3852743A4/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140323483A1 (en) * | 2007-11-07 | 2014-10-30 | University Of Massachusetts | Type iii secretion inhibitors, analogs and uses thereof |
US20130028989A1 (en) * | 2010-02-05 | 2013-01-31 | Indiana University Research And Technology Corporation | Materials and method for inhibiting replication protein a and uses thereof |
US20170182055A1 (en) * | 2010-02-05 | 2017-06-29 | Indiana University Research And Technology Corporation | Materials and method for inhibiting replication protein a and uses thereof |
WO2018001973A1 (en) * | 2016-06-29 | 2018-01-04 | Laboratorios Del Dr. Esteve S.A. | Pyrazole derivatives having activity against pain |
Non-Patent Citations (1)
Title |
---|
See also references of EP3852743A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20210155609A1 (en) | 2021-05-27 |
EP3852743A4 (en) | 2022-06-15 |
EP3852743A1 (en) | 2021-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI500622B (en) | Heterocyclic derivatives | |
CN112312904A (en) | Spiro compounds | |
AU2014267974B2 (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
KR20200112895A (en) | Heart eradication inhibitor | |
AU2011252974A1 (en) | Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
JP2020510642A (en) | o-Aminoheteroarylalkynyl group-containing compound and its production method and use | |
EP3065738A1 (en) | Compositions and methods for modulating farnesoid x receptors | |
UA44332C2 (en) | DERIVATIVES OF 2 (1H) -CHINOLINON AS SEROTONINE ANTAGONISTS, METHOD OF PREPARATION (OPTIONS), MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION OF | |
KR20120129869A (en) | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
PT2142533E (en) | Imidazolidinone derivatives | |
JP2016504282A (en) | Dihydropyrazole GPR40 modulator | |
KR20130046436A (en) | Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same | |
JP7025555B2 (en) | Inhibition of transient receptor potential A1 ion channels | |
CN108430969B (en) | Heterocyclic substituted N-sulfonyl benzamide derivative, preparation method and medical application thereof | |
JP2021529185A (en) | Cardiac sarcomere inhibitor | |
JP2021529746A (en) | Cardiac sarcomere inhibitor | |
JP2004067629A (en) | Mitochondria function-activating agent and new benzimidazole derivative | |
WO2016148232A1 (en) | Morphinan derivative | |
JP6782763B2 (en) | New pyridinium compound | |
BR112018016446B1 (en) | HALO-SUBSTITUTED PIPERIDINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND AND THERAPEUTIC USE THEREOF | |
EP3044223B1 (en) | 2,3-dihydro-1h-inden-1-one derivatives as retinoic acid-related orphan receptor gamma (ror gamma) antagonists for treating multiple sclerosis | |
WO2008053863A1 (en) | Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton | |
JP6526064B2 (en) | Pyridopyrimidinedione derivatives | |
WO2023232069A1 (en) | Azaquinolinone derivative, preparation method therefor and use thereof | |
WO2006093226A1 (en) | Antipruritic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19862398 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019862398 Country of ref document: EP Effective date: 20210419 |